# VOLUME 54 · AUTHOR INDEX

A = Abstract C = Correspondence L = Leader MA = Matters arising R = Review


Abbiati G, 144
Abney E, 777 (A)
Adams A, 768 (A)
Adams LM, 182
Adams S, 930
Adorini L, 759 (A)
Agea E, 382
Ahern MJ, 245
Ahmadi K, 216
Aho K, 811
Aiach M, 860 (L)
Aicher W, 524 (A)
Aissa J, 140
Akehurst R, 863 (L)
Al-Saffar N, 201, 404, 526 (A)
Ala'Aldeen DA, 117
Alam CAS, 766 (A), 777 (A)
Alaranta H, 494
Alarcón GS, 708
Alessio M, 193
Alexander J, 761 (A)
Alexopoulou L, 767 (A)
Algra D, 721
Alhenc-Gelas M, 860 (L)
Ali SY, 339
Allen R, 366
Åman S, 886
Amano T, 934 (C)
Amento EP, 760 (A)
Amer G, 530 (C)
Amor B, 137
Anand P, 251
Anaya J-M, 748
Anderle SK, 524 (A)
Andersson J, 654
Andersson U, 525 (A), 654
Andrew D, 366
Antoine J-F, 681
Anttila P, 305
Archer CB, 435 (A)
Archer JR, 544
Arenas J, 491
Arinbjarnarson S, 578
Arnoux B, 140
Aromaa A, 811
Arrigoni M, 144
Arthur V, 776 (A)
Aruffo A, 762 (A)
Asculai SS, 766 (A)
Ashton BA, 466
Athanasou NA, 392
Atherton A, 111
Atta MS, 117
Awerbuch M, 331 (L), 859 (MA)
Aydintug O, 610 (C)
Ayral X, 613 (L)
Azam Z, 527 (A)

Bacarini L, 772 (A)
Badley EM, 850
Baethge BA, 69, 780 (C)
Bagga MR, 25
Bahadir S, 726
Baici A, 281, 289
Bajocchi G, 636
Balazs EA, 527 (A)
Baldoncini R, 730
Band PA, 527 (A)
Bannwarth B, 681
Bansal S, 216
Barendsen BC, 525 (A)
Barrier JH, 587
Barrington NA, 801, 867
Barthel HR, 948
Bartucci F, 144
Bas S, 498
Bassendine M, 229
Bassey EJ, 861 (L)
Battafarano N, 774 (A)
Bax DE, 801
Bayley IJL, 571
Bayliss MT, 435 (A)
Bayrak S, 770 (A)
Beatty DW, 740
Belch JJF, 197, 853
Bell AL, 910
Bellamy N, 692 (L)
Bellisai F, 770 (A)
Belzunegui J, 780 (C)
Benveniste J, 140
Berg PA, 233 (C)
Berkovitch M, 277
Berthelot J-M, 76 (MA)
Bertotto A, 382
Bestard X, 530 (C)
Betzing KW, 69
Bhoola KD, 345
Bijlsma JWJ, 836
Bijzet J, 525 (A)
Billaud E, 587
Binder A, 216
Binelli L, 144
Birchall A, 763 (A)
Bishop J, 763 (A)
Bistoni O, 382
Bittar BF, 607 (C)
Bläß S, 355
Black C, 111
Blake DR, 59, 94, 670
Blake S, 366, 591
Blanco FJ, 881
Bletry O, 233 (C)
Bliddal H, 189
Blumsohn A, 867
Bodmer M, 366
Bogduk N, 100
Boiardi L, 640
Bologna C, 39
Bolten W, 556
Bonnefoy J-Y, 775 (A)
Bontrop R, 760 (A)
Bontrop RE, 773 (A)
Boonen A, 437 (C)
Boonen S, 437 (C)
Borretzen M, 760 (A)
Bottomley KM, 765 (A)
Bottoni U, 730
Bou-Gharios G, 111
Boumpas DT, 766 (A)
Bourke BE, 174
Bouter LM, 959
Bradbury JA, 934 (C)
Bradshaw CR, 263
Bradshaw D, 763 (A), 765 (A)
Brandt KD, 685 (MA)
Braun J, 774 (A)
Breedveld FC, 701, 768 (A), 773 (A)
Brennan FM, 767 (A)
Brennan P, 694 (L)
Bresnihan B, 389, 511, 526 (A), 772 (A)
Broadhurst MJ, 765 (A)
Broadley P, 539
Brodack J, 525 (A)
Brown D, 366
Brown KA, 916
Brown PA, 765 (A)
Brown RR, 524 (A)
Brühlmann P, 461
Bruyn GAW, 159 (R)
Bucci R, 774 (A)
Buchanan N, 604
Buckland-Wright JC, 263, 872
Bucknall RC, 778 (A), 930
Burger D, 766 (A)
Burmester GR, 904, 948
Bywaters EGL, 615

C-Soriguer FJ, 609 (C)
Cabello A, 491
Cambridge J, 696
Cammisa M, 772 (A)
Campion G, 764 (A)
Campos Y, 491
Cancio J, 780 (C)
Candell J, 687 (C)
Capell HA, 137, 197
Carlesimo M, 730
Carruthers DM, 927
Carsons SE, 413
Carty JE, 78 (C)
Carvajal I, 782 (C)
Casa-Alberighi OD, 774 (A)
Casey EB, 566
Cassar-Pullicino VN, 539
Cassinotti P, 498
Castillo MJ, 386
Catapano G, 328 (C)
Catterall C, 366
Cauli A, 209, 771 (A)
Cawley MID, 125, 179
Cawston TE, 571
Cerase A, 772 (A)
Cesarotti M, 382
Challacombe S, 209
Chaplin L, 366
Chapman B, 825
Chatard C, 687 (C)
Chen T-Y, 148
Chernajovsky Y, 768 (A)
Cheung KMC, 168
Chevalier X, 20
Chieco Bianchi F, 771 (A)
Ching DWT, 155 (MA)
Chinn R, 435 (A)
Cho C-S, 988
Chou C-T, 128, 321
Chou M-J, 148
Chowdhary RK, 776 (A)
Choy EHS, 767 (A), 771 (A)
Ciccarelli A, 775 (A)
Çimsit G, 726
Cingel B, 298
Claassen E, 762 (A)
Clunie GPR, 435 (A), 528 (A)
Coggeshall M, 761 (A)
Coggon D, 179
Cohen BJ, 535 (L)
Cohen IR, 762 (A)
Collantes E, 609 (C)
Collidge TA, 853
Collier J, 229
Collins DA, 174
Colston MJ, 59
Colville-Nash PR, 777 (A)
Colwell A, 867
Comerford FR, 436 (A), 527 (A)
Cooke ED, 197
Cooper C, 1 (L), 49, 179
Coquerelle P, 815
Coral A, 333
Cortet B, 815
Coumbe A, 59
Coupland C, 49
Couret I, 39
Covelli M, 774 (A)
Cowman MK, 527 (A)
Cozzi E, 771 (A)
Cozzi L, 771 (A)
Crawford N, 916
Crilly A, 137
Croft P, 735, 965
Csiki Z, 529 (MA)
Cunnane G, 772 (A)
Cunningham P, 216
Czernichow P, 375
Czirják L, 529 (MA), 856

Da Silva JAP, 6 (R)
Dahlberg L, 685 (MA)
Dalton S, 571
Dalum I, 773 (A)
Daragon A, 375
Darling JM, 436 (A)
David CS, 760 (A)
Davidson J, 311
Davies AM, 539
Davis P, 763 (A)
Dayer J-M, 766 (A)
De Candia A, 771 (A)
de Jong BA, 959
De La Mata J, 881
de las Heras G, 77 (C)
de Paulis A, 775 (A)
de Vries N, 601
Deger O, 726
Dehais J, 681
Delcambre B, 815
Della Casa-Alberighi O, 772 (A)
Dellestable F, 686 (MA)
Dell'omo G, 328 (C)
Dequeker J, 437 (C)
der Crescenzo D, 775 (A)
Deutsch E, 525 (A)
Deutsch K, 525 (A)
Dévényi K, 856
Devlin J, 776 (A)
Di Francesco L, 730
Dieppe P, 825
Dieppe PA, 345
Dijkmans BAC, 701, 773 (A)
Dimitrijevic M, 764 (A)
Dirksen U, 846
Dixey J, 269, 841
Dodds RA, 841
Doeglas D, 455
Doherty M, 53, 86, 337, 891
Dolan AL, 532 (C)
Dölling R, 770 (A)
Domlijan Z, 764 (A)
Doran MC, 466
Dörner T, 904
Dougados M, 137, 613 (L)
Dowling JP, 796
Drummond AH, 765 (A)
D'Souza E, 748
Du-Boutin LTH, 860 (L)
Duff GW, 601
Duits A, 836
Dunphy J, 269
Duquesnoy B, 815
Durr A, 375
Dybwad A, 216
Dyer PA, 311

Eastell R, 801, 867
Eberhardt K, 45
Ebringer A, 216, 607 (MA)
Eden J, 245
Edwards JCW, 235 (L), 389, 395, 435 (A), 525 (A), 528 (A), 696, 841
Edwards SW, 778 (A), 930
Egger P, 179
Eggleton P, 916
Eguchi K, 713
Eichbaum QG, 740
Eijsbouts A, 772 (A)
El-Ghazali M, 777 (A)
Ell PJ, 435 (A), 528 (A)
Elliot L, 763 (A)
Elliot M, 767 (A)
Elsner H, 773 (A)
Elson CJ, 345
Emery P, 770 (A), 776 (A), 863 (L), 944
Emmrich F, 501, 846
Emtage S, 366
Engström GN, 256
Engström-Laurent A, 435 (A)
Epstein JE, 740
Ercolani R, 382
Estevez M, 782 (C)
Etherington J, 936 (C)
Ettelaie C, 216
Etwebi AB, 436 (A), 527 (A)
Eulderink F, 615
Euler HH, 936 (C)
Evans CH, 769 (A)
Evans N, 539
Evans PR, 125

Fairburn K, 94
Fantini F, 774 (A)
Fatout E, 681
Fauler J, 820
Fearon DT, 763 (A)
Federlin K, 556
Feldmann M, 767 (A), 768 (A), 777 (A)
Ferraccioli GF, 772 (A)
Ferrara R, 144, 772 (A)
Ferri C, 328 (C), 730
Fex E, 45
Fielder M, 216
Fiocco U, 771 (A)
Fiorucci G, 382
Fish S, 404
FitzGerald O, 511, 526 (A), 772 (A)
Fitzmaurice RJ, 436 (A)
Flipo R-M, 815
Flower CDR, 17
Fonollosa V, 687 (C)
Formiga F, 274
Forre O, 216, 768 (A)
Forrest L, 759 (A)
Foster H, 229
Foulkes R, 366
Foy TM, 762 (A)
François RJ, 615
Franková D, 325
Fraser JRE, 429
Froes L, 604
Frölich JC, 820, 942 (L)
Fujikawa Y, 318
Fujimori Y, 477
Fumagalli M, 807

Gaál J, 856
Gabay CEM, 76 (MA)
Gaffney K, 379, 670
Galeazzi M, 770 (A)
Gallo C, 771 (A)
Garber SJ, 435 (A)
García-Lozano JR, 386
García-Vadillo A, 782 (C)
Gardner DL, 436 (A)
Gardner-Medwin D, 536 (L)
Gascó J, 530 (C)
Gaston H, 157 (L)
Gaucher A, 686 (MA)
Gay R, 524 (A)
Gay RE, 764 (A)
Gay S, 524 (A), 764 (A)
Gazarian M, 277
Geborek P, 45, 528 (A)

Geczy AF, 329 (L)
Geiler T, 524 (A)
Georgopoulos S, 767 (A)
Gerli R, 382
Geusens P, 437 (C)
Ghesquiere B, 437 (C)
Gialamas GG, 107
Gibson K, 678, 687 (C)
Gibson V, 763 (A)
Gillet P, 686 (MA)
Gimsa U, 773 (A)
Glimcher LH, 436 (A)
Glowacki J, 436 (A)
Gockel M, 494
Godeau B, 991
Godeau P, 233 (C), 860 (L)
Gohchi K, 73
Goldenberg DL, 3 (L)
Goldman AI, 527 (A)
Goldring SR, 436 (A)
Gomez A, 687 (C)
Gomez N, 582
Gomez-Reino JJ, 491
Gómez-Reino JJ, 881
González-Alvaro I, 782 (C)
González-Escribano MF, 386
Gonzalez-Gay M, 760 (A)
Goodstone NJ, 466
Goto T, 732
Gotoh M, 73
Gough A, 776 (A)
Goulding NJ, 841
Govoni M, 636
Graef V, 556
Granfors K, 631
Gravallese EM, 436 (A)
Greenham A, 763 (A)
Greenwood J, 774 (A)
Greiner DL, 762 (A)
Grey HM, 761 (A)
Griffiths B, 863 (L)
Griffiths I, 229
Griffiths M, 760 (A)
Grobbee DE, 721
Grolms M, 774 (A)
Gross WL, 233 (C)
Gu X-H, 744
Guillevin L, 991
Guinot P, 140
Guo K, 229
Gürler A, 610 (C)

Hachulla E, 991
Hacking JC, 17
Hafler DA, 761 (A)
Hakala M, 886
Häkkinen T, 831
Hale G, 774 (A)
Hall N, 566
Hall-Craggs M, 435 (A)
Hallam T, 763 (A)
Hallam TJ, 765 (A)
Hallé O, 681
Halliwell B, 505
Hamblem DL, 527 (A)
Hamblen DL, 25
Hamerman D, 82 (R)
Hamilton JA, 528 (A)
Hammer J, 775 (A)
Hammoudeh M, 131
Han H, 988
Hannon R, 867
Hannonen P, 597
Harada Y, 436 (A)
Hardingham T, 366
Hardingham TE, 591
Harmer I, 471
Harper GP, 662
Harris W, 763 (A)
Harvey A, 333
Hassan WU, 308
Haugen M, 216
Hay EM, 311
Hazleman BL, 152, 571
Healy S, 66
Hedin H, 435 (A)
Hegedüs I, 856
Heinegård D, 685 (MA)
Heingård D, 528 (A)
Heliövaara M, 811
Helliwell PS, 924
Hellström S, 435 (A)
Helsen MA, 766 (A)
Hembry RM, 25, 527 (A)
Henderson B, 366, 389, 519, 591
Hendricks S, 761 (A)
Hermus A, 772 (A)
Hernigou P, 20
Hertzberger-ten Cate R, 701
Hesse M, 770 (A)
Hesselton RA, 762 (A)
Heywood B, 825
Hiepe F, 904
Hietanen J, 744
Higashino K, 90, 351
Hill C, 763 (A)
Hill CH, 765 (A)
Hilliquin P, 140
Hindersson P, 773 (A)
Hino K, 524 (A)
Hironaka K, 934 (C)
Hoaglund FT, 107
Hobbs RN, 466
Hoebe B, 754
Hoekstra M, 781 (C)
Hoerrner LA, 685 (MA)
Hofman A, 721
Hohmann A, 471
Holcombe RF, 69
Holland CD, 308
Holmdahl R, 770 (A)
Holthuysen AEM, 526 (A)
Hopkinson ND, 451, 891
Hörler D, 281, 289
Horneff G, 846
Hortas C, 77 (C)
Hosoi E, 732
Hucko M, 904
Hughes EJ, 740
Hughes GRV, 604
Huissoon A, 776 (A)
Huizinga TWJ, 773 (A)
Hunter A, 529 (C)
Huong DLT, 233 (C)
Huong Du LT, 991
Hutchings A, 763 (A)
Hutton CW, 237 (R)

Iaccarino E, 193
Iamaroon A, 776 (A)
Iammarrone CS, 193
Iannone F, 774 (A)
Ichikawa Y, 484
Ida H, 713
Ide M, 484
Incorvaia C, 807
Inkinen R, 831
Inoko H, 983
Inoue H, 995
Iribarren JA, 780 (C)
Irvine AE, 910
Isenberg D, 689 (L)
Isenberg DA, 471, 767 (A), 787 (R)
Issacs JD, 774 (A)
Ivanyi P, 754

Jajic I, 764 (A)
James WH, 531 (C)
Jaroma H, 831
Jarrousse B, 991
Jasani MK, 263
Jensen MR, 773 (A)
Jeracitano G, 328 (C)
Joannou C, 216
Johnson WH, 765 (A)
Johnsson K, 45
Jolliffe VA, 251, 670
Jones A, 53
Jones P, 94
Jonker M, 760 (A), 773 (A)
Jónsson T, 578
Joosten LAB, 526 (A), 645, 766 (A), 976
Jorgensen C, 39
Julià MR, 530 (C)
Jurmain RD, 443 (R)

Kaburaki J, 983
Kadoya Y, 201
Kamminga J, 525 (A)
Kandola L, 529 (C)
Kanerud L, 256
Kano S, 361
Karran EH, 662
Kary S, 761 (A)
Kassimos D, 767 (A)
Katsikis PD, 777 (A)
Kauppi M, 305, 886
Kavanagh RT, 152
Kawabe Y, 713
Kawasaki H, 934 (C)
Keaney NP, 308
Kearns G, 566
Kelleher D, 566
Kelly CA, 308
Kerslake S, 604
Keystone EC, 608 (C)
Keyszer G, 524 (A)
Khamashta MA, 604
Khazaei HA, 314
Khwaja HA, 526 (A)
Kidd BL, 125, 251
Kilgore L, 443 (R)
Kim H-Y, 988
Kim T-G, 988
King RH, 152
Kingsley GH, 757, 759 (A), 767 (A), 771 (A)
Kinne RW, 501
Kirby JDT, 197
Kirwan J, 781 (C)
Kissling R, 281, 289
Kiviranta I, 831
Kjeldsen-Kragh J, 216, 607 (MA)
Klareskog L, 525 (A), 654
Klein R, 233 (C)
Knekt P, 811
Knolle P, 560
Koes BW, 959
Koh W-H, 269
Koh WH, 779 (MA)
Kollias G, 767 (A)
Kolta S, 137
Konttinen YT, 744
Koren G, 277
Koski H, 744
Kosunen TU, 437 (C)
Kriegsmann J, 524 (A), 764 (A)
Krol B, 455
Kuis W, 775 (A)
Kumar L, 134
Kuwana M, 983
Kwong YL, 155 (C)

La Civita L, 328 (C)
La Corte R, 636
Laan R, 772 (A)
Lad N, 763 (A)
Lafeber FPJG, 836
Lai N-S, 225
Lakomek H-J, 355
Lalor PA, 525 (A)
Lam D, 965
Lamont A, 763 (A)
Lan J-L, 225
Lanchbury J, 757
Lang A, 281, 289
Lanyon P, 735
Laoussadi S, 140
Lapadula G, 774 (A)
Laraki R, 233 (C)
Larget-Piet B, 20
Lark MW, 685 (MA)
Lascaratos J, 951
Latasa JA, 435 (A)
Lau CS, 155 (C), 197
Lau EMC, 965
Laurent C, 435 (A)
Laurent R, 100
Laurent T, 389
Laurent TC, 429
Laurent UBG, 429
Lauster R, 770 (A)
Lawton G, 763 (A), 765 (A)
Laxer RM, 277
Le CH, 796
Le Loët X, 375
Ledbetter JA, 762 (A)
Ledingham J, 53, 379
Lee HG, 527 (A)
Lee S-H, 988
Lee S-L, 148
Lehnert H, 233 (C)
Lehtinen K, 631
Leirisalo-Repo M, 437 (C), 631
Lemon M, 345
Lems WF, 779 (MA)
Leoni L, 774 (A)
Lequen L, 681
Leslie A, 245
Lesprit P, 860 (L)
Levick JR, 389, 417, 435 (A)
Levy JG, 776 (A)
Lewis EJ, 765 (A)
Lewis J, 763 (A)
Lewthwaite J, 366, 591
Lillo JA, 609 (C)
Lim KL, 117
Lima F, 604
Limburg PC, 33, 525 (A), 674
Lin F, 965
Lin R-H, 225
Linblad S, 525 (A)
Lindblad S, 389, 654
Lindholm H, 494
Lindholm T, 494
Lindquist A, 494
Lipsky PE, 762 (A)
Lisse JR, 780 (C)
Littman BH, 435 (A)
Liu GT, 748
Lloyd Jones JK, 626
Loew-Friedrich I, 764 (A)
Lohmander LS, 524 (A), 685 (MA)
Long A, 566
López-Arias MJ, 77 (C)
López-Bote JP, 782 (C)
Louvel JP, 375
Luan X, 748
Lukey PT, 775 (A), 776 (A)
Lunardi C, 314
Luthra H, 760 (A)
Luukkainen R, 597, 886
Lynch JA, 263

Maatela J, 811
Macaluso M, 708
McCarty DJ, 939 (L)
Macchioni P, 640
McDermott E, 78 (C)
McDonald JN, 417
McFarlane AC, 245
Macfarlane DG, 263, 872
McHugh NJ, 269, 779 (MA)
McIlraith M, 762 (A)
McKane R, 910
Mackworth-Young CG, 471
McNally T, 471
McNaught PJ, 100
Mader R, 608 (C)
Madhok R, 137, 197
Maeda S, 970
Magadur-Joly G, 587
Magill MK, 910
Mah JTL, 201
Maheshwaran S, 539
Mahmood A, 525 (A)
Maillefert JF, 687 (C)
Mainardi J-L, 991
Maini RN, 767 (A), 777 (A)
Major G, 229
Mäki-Ikola O, 631
Makino H, 934 (C), 937 (C)
Maksymowych WP, 128, 321
Maldini MC, 640
Malmström M, 744
Malmström V, 770 (A)
Mancini R, 640
Månsson B, 528 (A)
Mapp PI, 59, 398
Marcé S, 681
Marchesoni A, 774 (A)
Marcolongo R, 770 (A)
Marhoffer W, 556
Marinò I, 775 (A)
Markwell RE, 662
Marone G, 775 (A)
Marotta A, 193
Martin L, 77 (C)
Marty M, 20
Marubini E, 772 (A)
Mason RM, 435 (A)
Masoud I, 556
Masson C, 587
Masumi S, 318
Masuyama J, 361
Matamoros N, 530 (C)
Matsuda J, 73
Mayet W, 560
Mayet WJ, 904
Mejjad O, 375
Memsiş Ö, 726
Menkes CJ, 140
Menon S, 787 (R)
Merlin C, 281, 289
Mertz A, 774 (A)
Metzler B, 761 (A)
Meyer O, 76 (MA)
Meyer zum Büschenfelde K-H, 560
Meyers OL, 775 (A), 776 (A)
Michel BA, 461
Mihajlovic D, 764 (A)
Milà J, 530 (C)
Miltenburg AMM, 768 (A)
Mimori A, 361
Minota S, 361
Mitchell M, 49
Mitchison A, 770 (A)
Mitchison NA, 761 (A)
Mitjavila F, 274
Mizokami A, 713
Mizushima Y, 484
Mladenovic V, 764 (A)
Moga I, 274
Mok CC, 155 (C)
Monoghan P, 111
Montaña E, 582
Moore AR, 527 (A)
Moore DJ, 801
Moore TL, 76 (MA)
Morales J, 386
Morand EF, 841
Moreland LW, 767 (A), 769 (A)
Morelli S, 730
Morey A, 530 (C)
Morishita Y, 937 (C)
Morita Y, 937 (C)
Moriwaki Y, 90, 351
Morozzi G, 770 (A)
Morris CJ, 59
Möttönen T, 597
Mouritsen S, 773 (A)
Mueller GM, 768 (A)
Muir KR, 891
Muirden KD, 796
Mukherjee SKM, 451
Mulder AHL, 525 (A)
Mulherin D, 526 (A)
Müller-Ladner U, 524 (A)

Muller-Ladner U, 764 (A)
Mulqueen M, 763 (A)
Murakami K, 934 (C)
Murakami T, 995
Murphy A, 566
Murphy E, 197
Murray T, 763 (A)
Muscat C, 382
Musikic P, 764 (A)
Myers SL, 433, 685 (MA)

Nabozny GH, 760 (A)
Nagataki S, 713
Nagy Z, 529 (MA)
Nagy ZA, 775 (A)
Nakagawa M, 484
Nakanishi M, 732
Natour J, 140
Natvig JB, 760 (A)
Nazhat NB, 94
Nelson PN, 441 (L)
Nesbitt A, 366
Nesher G, 76 (MA)
Neyndorff H, 776 (A)
Nicol PD, 608 (C)
Nieminen P, 886
Nikkari S, 597
Nishida K, 995
Nissilä M, 631
Nitti F, 807
Nixon J, 763 (A)
Nixon JS, 765 (A)
Noelle RJ, 762 (A)
Nolla JM, 274, 582
Nordin H, 189
Nuñez-Roldán A, 386

Odding E, 721
Oed C, 764 (A)
Ogawa N, 748
Ogura T, 937 (C)
Oh V, 687 (C)
Oishi CS, 107
Okano Y, 983
Oliver MA, 891
Ollier WER, 311
Olsen I, 111
Omary MB, 566
Omoto H, 970
O'Reilly S, 86
Örem A, 726
Orgles CS, 333
Origuchi T, 713
Osanai A, 484
Osborn TG, 76 (MA)
Osei D, 404
Osman J, 111
Ota Z, 934 (C), 937 (C)
Otová B, 325
Ovali E, 726
Owen S, 687 (C)
Özoran K, 610 (C)

Pac M, 274
Padula A, 774 (A)
Page D, 761 (A)
Paimela L, 437 (C)
Paley M, 435 (A)
Pallis M, 785 (L)
Palombo-Kinne E, 501
Panayi G, 771 (A)
Panayi GS, 209, 757, 759 (A), 767 (A), 771 (A), 779 (MA)
Papageorgiou AC, 850
Papo T, 233 (C)
Park S-H, 988
Parry S, 777 (A)
Pasero G, 772 (A), 774 (A)
Patel S, 174, 783 (L)
Pauzner R, 608 (C)
Peat ID, 66
Pedersen LM, 189
Pedrinelli R, 328 (C)
Peel NFA, 801, 867
Peere T, 687 (C)
Pego JM, 780 (C)
Peh WCG, 168
Penhallow J, 916
Pennec YL, 587
Pepper L, 311
Pere P, 686 (MA)
Perez-Bocanegra C, 687 (C)
Pérez-Lindón G, 609 (C)
Perkins P, 776 (A)
Perry JD, 379
Piette J-C, 233 (C), 860 (L), 991
Pile K, 678, 687 (C)
Pipitone V, 774 (A)
Pirozzi M, 193
Pitsillides A, 435 (A)
Pitsillides AA, 841
Pitzalis C, 209, 765 (A)
Plater-Zyberk C, 775 (A)
Plows D, 767 (A)
Podhajcer OL, 768 (A)
Pole D, 763 (A)
Polito C, 193
Pons-Romero F, 77 (C)
Pope D, 735
Popovic M, 764 (A)
Portioli I, 640
Potena A, 636
Powell RJ, 117, 891
Prakken ABJ, 775 (A)
Prehm P, 408
Price FM, 435 (A)
Prigent D, 527 (A)
Primary Care Rheumatology Society, 735
Priolo F, 772 (A)
Probert L, 767 (A)
Properzi G, 730
Prost A, 587

Quayle JA, 778 (A), 930
Quintner J, 859 (MA)

Raccari E, 776 (A)
Ragno S, 59
Rahman A, 689 (L)
Rahman MM, 345
Ralston SH, 66
Rankin ECC, 767 (A)
Rashid T, 216, 607 (MA)
Rasooly I, 850
Ratcliffe LT, 775 (A), 776 (A)
Ratkay LG, 776 (A)
Ravirajan CT, 471
Rea L, 193
Rebello P, 774 (A)
Reece RJ, 776 (A)
Regan M, 53, 626
Reid DM, 66
Rémy J, 815
Rémy-Jardin M, 815
Remy P, 991
Renou P, 587
Ress SR, 775 (A), 776 (A)
Reunanen A, 811
Reveille JD, 780 (C)
Revell PA, 201, 404, 526 (A)
Reynolds JJ, 25, 527 (A)
Riario-Sforza GG, 807
Riccieri V, 776 (A)
Richards SCM, 451
Richter AM, 776 (A)
Rigon C, 771 (A)
Rijkers GT, 775 (A)
Riley GP, 571
Risteli J, 886
Risteli L, 886
Robbins PD, 768 (A)
Roberts-Thomson PJ, 245
Robins RA, 785 (L)
Roig Escofet D, 582
Roig-Escofet D, 274
Roivainen A, 597
Roos H, 685 (MA)
Rose CD, 607 (C)
Ross D, 229
Rossi F, 640
Rossi M, 39
Rossini AA, 762 (A)
Roudot-Thoraval F, 991
Rozadilla A, 582
Rozman B, 764 (A)
Rubaltelli L, 771 (A)
Rudd CE, 763 (A)
Rudwaleit M, 678, 687 (C)
Ruiu G, 774 (A)
Ruppert J, 761 (A)
Russell AS, 128, 321
Ryan LM, 939 (L)

Sahinoglu T, 94
Saito S, 732
Saitoh N, 73
Sakurai M, 970
Salmon M, 944
Salvarani C, 640
Sánchez B, 386
Sánchez Guijo P, 609 (C)
Sánchez-Román J, 386
Sanderman R, 455
Santucci A, 730
Sany J, 39
Sarkar B, 134
Sawai T, 970
Saxne T, 528 (A), 685 (MA)
Scavalli AS, 776 (A)
Scazzoso A, 807
Schaeffer A, 991
Schaeverbeke T, 681
Schantz A, 771 (A)
Scheja M, 556
Schlaak JF, 560
Schlievert PM, 524 (A)
Schnabel A, 233 (C)
Schneider EM, 355
Scholtens E, 775 (A)
Schreier MH, 764 (A)
Schröder F, 936 (C)
Schroeder JO, 936 (C)
Schulze-Koops H, 846
Schumacher HR, 389, 516
Schwab JH, 524 (A)
Schwarting A, 560
Schwarzer AC, 100
Schwochau M, 355
Scotchford CA, 339
Scott BB, 78 (C)
Scott DGI, 927
Scott DL, 769 (A)
Seed MP, 527 (A), 766 (A), 777 (A)
Sehgal VJ, 608 (C)
Seifert H, 764 (A)
Seki M, 970
Sensi F, 776 (A)
Sette A, 761 (A)
Seward H, 825
Sharma A, 780 (C)
Shimizu K, 477
Shingu M, 318
Shiozawa S, 524 (A)
Short S, 366
Shortkroff S, 435 (A), 525 (A)
Siam ARM, 131
Siegl G, 498
Sieper J, 761 (A), 774 (A)
Silman A, 694 (L), 965
Silman AJ, 311
Silverman ED, 277
Simeon CP, 687 (C)
Simkin P, 389
Simkin PA, 424, 611 (L)
Singh D, 94
Singh K, 708
Sinigaglia F, 775 (A)
Sinigaglia L, 144
Sioud M, 216
Skurkovich B, 777 (A)
Skurkovich S, 777 (A)
Sledge CB, 435 (A), 525 (A)
Smeathers JE, 182
Smith MD, 779 (MA)
Smith RM, 762 (A)
Smith RW, 179
Snape J, 626
Snoke K, 761 (A)
So AK, 314
Solans R, 687 (C)
Soler J, 582
Solinger AM, 762 (A)
Sopwith M, 767 (A)
Spadaro A, 776 (A)
Specker C, 355
Spector TD, 936 (C)
Spinozzi F, 382
Steinberg M, 197
Stephens S, 366, 767 (A)
Stewart RM, 69
Stichtenoth DO, 820
Strachan MWJ, 436 (A)
Stracke H, 556
Strand GM, 708
Strand V, 764 (A)
Strano CG, 193
Stucki G, 461
Stucki S, 461
Sturrock RD, 137
Suarez-Almazor M, 321
Sullivan JS, 329 (L)
Suurmeijer T, 455
Suzuki Y, 484
Svensson B, 189
Swan A, 825
Swanepoel MW, 182
Swannell AJ, 529 (C)
Sweep C, 772 (A)
Szomor Z, 477

Taglione E, 774 (A)
Takahashi S, 90, 351
Takahashi Y, 970
Takeda A, 361
Talal N, 748
Tammi M, 831
Tanihara M, 484
Tarkowski A, 256
Tartoni P, 640
Tavernier C, 687 (C)
Taylor PC, 527 (A)
te Koppele JM, 773 (A)
Tebib J, 687 (C)
Tennant A, 439 (L)
Terkeltaub RA, 79 (L)
Tetlow LC, 525 (A), 549, 896
Thapa BR, 134
t'Hart BA, 760 (A), 773 (A)
Thompson KM, 760 (A)
Thompson RC, 591
Thomson W, 311
Thornhill TS, 525 (A)
Thorsteinsson H, 578
Thorsteinsson J, 578
Tikly M, 678
Tinahones FJ, 609 (C)
Tiwana H, 216
Todd I, 117
Todesco S, 771 (A)
Todisco N, 193
Toivanen P, 597
Tokgöz N, 610 (C)
Torisu T, 318
Tóth E, 529 (MA)
Trabandt A, 524 (A)
Tracy IC, 708
Trancart MM, 527 (A)
Travisi T, 807
Trefzer U, 904
Tregnaghi A, 771 (A)
Trotta F, 636
Tsay GJ, 148
Tsukamoto M, 73
Tsutsumi Z, 90, 351
Turley JJ, 608 (C)
Tutkak H, 610 (C)

Ulfgren A-K, 525 (A), 654
Uriarte E, 780 (C)
Uzuki M, 970

Väätäinen U, 831
Vaidya S, 780 (C)
Valdimarsson H, 578
Valesini G, 730
Valkenburg HA, 721
van de Loo FAJ, 526 (A), 766 (A), 976
van de Putte L, 772 (A)
van de Putte LBA, 526 (A), 601
van de Stadt RJ, 779 (MA)
van den Berg WB, 526 (A), 645, 766 (A), 976
van den Bersselaar LAM, 526 (A)
van den Hoogen F, 772 (A)
van der Windt DAWM, 959
van Eden W, 775 (A)
van Leeuwen M, 455
van Leeuwen MA, 33, 674
van Lent PLE, 766 (A)
van Lent PLEM, 526 (A)
van Marle J, 645
van Rensen L, 773 (A)
van Riel PLCM, 33, 674
van Rijswijk M, 455
van Rijswijk MH, 33, 674, 770 (A)
van Roon JAG, 836
van Roy JLAM, 836
van Schaardenburg D, 779 (MA)
Vancheeswaran R, 111
Vandenouweland FA, 721
Varenna M, 144
Vautier G, 78 (C)
vd Zee R, 775 (A)
Veale DJ, 853
Vecchio PC, 152
Veltrandi E, 640
Vennart W, 237 (R)
Vernhes J-P, 681
Verschure PJ, 645, 976
Verweij CL, 773 (A)
Vilardell M, 687 (C)
Viljanen A, 494
Vischer TL, 498
Vittecoq O, 375

Wadsworth J, 763 (A)
Wahn V, 846
Waldmann H, 774 (A)
Walia BNS, 134
Walmsley M, 777 (A)
Walters G, 934 (C)
Wang JT, 436 (A)
Wang L, 916
Wang S, 100
Ward RJ, 872
Waterfield JD, 776 (A)
Watson F, 778 (A)
Watts RA, 927
Wechsler B, 860 (L)
Weinreich S, 754
Weissman BN, 435 (A)
Westhovens R, 437 (C)
Westra J, 33, 525 (A), 674
Whittle A, 765 (A)
Whyte J, 269
Wilkinson ID, 435 (A)
Wilkinson LS, 525 (A), 528 (A), 841
Wilkinson S, 763 (A)
Williams D, 763 (A)
Williams DG, 527 (A)
Williams R, 767 (A), 777 (A)
Williams RB, 670
Williams SA, 872

Willoughby DA, 527 (A), 766 (A), 777 (A)
Wilson AG, 601
Wilson C, 216
Wilson PJ, 125
Winalski CS, 435 (A)
Winchester R, 389
Wing M, 774 (A)
Winrow VR, 59
Wofsy D, 762 (A)
Wolf J, 413
Wolf RE, 69
Woody J, 771 (A)
Wooley PH, 298
Woolf AD, 535 (L)
Woolley D, 389
Woolley DE, 525 (A), 533 (L), 549, 896
Wordsworth P, 678, 687 (C)
Worthington J, 311
Wraith DC, 761 (A), 762 (A)
Wrigglesworth J, 216
Yamamoto S, 477
Yamamoto T, 90, 351
Yamamura M, 937 (C)
Yamamuro T, 477
Yamashita I, 713
Yanni G, 209, 771 (A)
Yli-Jama T, 597
Yokoi K, 732
Yoshio T, 361
Young TJ, 662
Yu C-L, 225
Zanelli E, 760 (A)
Zegers BJM, 775 (A)
Zeidler H, 820
Zeni S, 774 (A)
Zeuner RA, 936 (C)
Zidek Z, 325
Zivkovic M, 764 (A)
Zoppini A, 776 (A)
Zuccaro C, 774 (A)

# VOLUME 54 · SUBJECT INDEX

**Acetabular dysplasia,** Osteoarthritis of the hip joint and acetabular dysplasia in women, **179**

**Activated protein C,** Activated protein C resistance caused by factor V Arg 506→Gln mutation has no role in thrombotic manifestations of Behçet's disease: *correspondence*, **860**

**Adhesion molecules**
- Cellular basis of rheumatoid joint destruction: expression of oncogenes, adhesion molecules and cartilage degrading enzymes, **524** *abst*
- Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis, **209**
- UDPGD activity and VCAM-1 in synovial like peri-implant tissues, **525** *abst*

**Adjuvant arthritis,** Lack of causal relationship between inducibility/severity of adjuvant arthritis in the rat and disease associated changes in production of nitric oxide by macrophages, **325**

**Adjuvant induced arthritis,** Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells, **484**

**Adult onset Still's disease,** Increased serum IgE level and interleukin-4 release from cultured lymphocytes from a patient with adult onset Still's disease, **752**

**Adult Still's disease,** Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France, **587**

**Ageing,** Clinical implications of osteoarthritis and ageing: *review*, **82**

**Aggrecan,** Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis, **528** *abst*

**Amino acid sequences,** Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and *Proteus mirabilis* in rheumatoid arthritis, **216**

**ANA negative status,** Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases: *matters arising*, **779**

**Anaemia,** Teenager with an irritable hip, anaemia and malaise: *masterclass*, **701**

**Angiogenesis,** Metalloproteinases, cytokines and angiogenesis, **765** *abst*

**Angiostatic steroid**
- Angiostatic steroid or angiogenic heparin treatment results in altered granuloma development and cartilage destruction, **777** *abst*
- Regression of granulomatous tissue neovasculature with angiostatic steroid therapy, **777** *abst*

**Ankylosing enthesopathy,** Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice, **754**

**Ankylosing spondylitis**
- Ankylosing spondylitis, IgA, and transforming growth factors: *hypothesis*, **544**
- Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis, **556**
- IgA1 and IgA2 subclass antibodies against *Klebsiella pneumoniae* in the sera of patients with peripheral and axial types of ankylosing spondylitis, **631**
- Immunohistological analysis of synovial membrane in ankylosing spondylitis: implications for immunotherapy, **772** *abst*
- Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis, **128**
- Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis, **321**
- The semeiology of arthritis: discriminating between patients on the basis of their symptoms, **924**

***Annals of the Rheumatic Diseases,*** Editorial activity and performance for 1994, **337**

**Annexins,** Differential distribution of annexins-I, -II, -IV, and -VI in synovium, **841**

**Antagonist peptides,** Mechanism of action of T cell receptor antagonist peptides, **761** *abst*

**Anterior uveitis,** Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis, **128**

**Antiandrogenic treatment,** Might patients with HLA-B27 related diseases benefit from antiandrogenic treatment? *correspondence*, **531**

**Antibodies**
- Effects of antibodies to the CD40 ligand (gp39) on cell and humoral mediated immunity, **762** *abst*
- Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus, **117**
- Specificity of antinuclear antibodies in primary biliary cirrhosis, **148**

**Anticentromere antibody,** HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), **983**

**Anticytoplasmic antibodies,** Characterisation of anticytoplasmic antibodies and their clinical associations, **269**

**Antigen induced arthritis**
- Effects of 166holmium-hydroxylapatite beads on the synovium of the antigen induced arthritis rabbit stifle, **525** *abst*
- Photodynamic treatment of antigen induced arthritis in rabbits, **776** *abst*
- Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies, **366**

**Anti-inflammatory medication,** Physicochemical properties of human synovial effusions in osteoarthritis patients discontinued from anti-inflammatory medication, **527** *abst*

**Antineutrophil cytoplasmic antibodies,** Antineutrophil cytoplasmic antibodies and the eosinophilia myalgia syndrome: *correspondence*, **233**

**Antinuclear antibodies,** Specificity of antinuclear antibodies in primary biliary cirrhosis, **148**

**Antiperinuclear factor,** Antiperinuclear factor in the polyarticular form of juvenile chronic arthritis: are use of frozen material or age of patients relevant? *matters arising*, **76**

**Antiphospholipid antibodies,** Prevalence of $\beta_2$-glycoprotein I antibody in systemic lupus erythematosus patients with $\beta_2$-glycoprotein I dependent antiphospholipid antibodies, **73**

**Antiphospholipid syndrome,** Homozygous complement factor deficiency and primary antiphospholipid syndrome: a clinical and serological study: *correspondence*, **530**

**Antirheumatic drugs,** Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients, **881**

**Anti-Scl-70 antibodies,** Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies, **69**

**Aortic aneurysm,** Vertebral fracture induced by chronic contained rupture of aortic aneurysm: *correspondence*, **437**

**Apolipoprotein E,** Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia, **351**

**Apoptosis,** Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid, **910**

**Arthritis**
- 'Arthritis' in Byzantium (AD 324-1453): unknown information from non-medical literary sources, **951**
- Association between human parvovirus B19 infection and arthritis, **498**
- IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints, **976**
- Illness behaviour in patients with arthritis, **245**
- Parvovirus B19 and chronic arthritis—causal or casual association? *leader*, **535**

**Arthropathy,** Progressive shoulder arthropathy, **168**

**Articular cartilage**
- Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis, **645**
- Immunohistochemical demonstration of fibronectin in the most superficial layer of normal rabbit articular cartilage, **995**
- Magnesium whitlockite deposition in articular cartilage: a study of 80 specimens from 70 patients, **339**

**Asymmetrical nodular osteoarthritis,** Asymmetrical nodular osteoarthritis in a patient with a hemiparesis: *correspondence*, **936**

**Atlantoaxial instability,** A stiff collar can restrict atlantoaxial instability in rheumatoid cervical spine in selected cases, **305**

**Autoantibodies**
- Induction of autoantibodies against a self protein, **773** *abst*
- Rheumatic fever: autoantibodies against a variety of cardiac, nuclear, and streptococcal antigens, **740**

**Autoantigens,** Autoantigens in rheumatoid arthritis, **759** *abst*

**Autoimmune disease**
- Central role of cytokines in the pathogenesis of autoimmune diseases and the immunotherapy of different autoimmune diseases, especially rheumatoid arthritis, **777** *abst*

Rheumatological manifestations of haematological diseases: *review*, **787**
The NOD mouse model—the development of strategies to treat human autoimmune disease, **759** *abst*
**Autoimmunity,** Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses: *review*, **6**
**Axon reflexes,** Assessment of cutaneous sensory and autonomic axon reflexes in rheumatoid arthritis, **251**
**Azathioprine,** Secondary acute myeloid leukaemia with 7q– complicating azathioprine treatment for rheumatoid arthritis: *correspondence*, **155**

**B cell death,** Is rheumatoid arthritis a failure of B cell death in synovium? *hypothesis*, **696**
**B lymphocyte activation,** Setting thresholds for B lymphocyte activation, **763** *abst*
**$B_2$-glycoprotein I antibody,** Prevalence of $\beta_2$-glycoprotein I antibody in systemic lupus erythematosus patients with $\beta_2$-glycoprotein I dependent antiphospholipid antibodies, **73**
**Behçet's disease (syndrome)**
Activated protein C resistance caused by factor V Arg 506 → Gln mutation has no role in thrombotic manifestations of Behçet's disease: *correspondence*, **860**
Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease, **726**
Relapsing polychondritis and Behçet's syndrome in a patient with HIV infection: *correspondence*, **780**
Serum levels of interleukin-8 in patients with Behçet's disease: *correspondence*, **610**
TAP polymorphism in patients with Behçet's disease, **386**
**Biochemical measurement,** Biochemical measurement of disease activity, **770** *abst*
**Bisphosphonates,** Treatment response in Paget's disease: *leader*, **783**
**BN 50730,** Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730, **140**
**Boerhaave, Herman,** Herman Boerhaave (1668–1738): *stamp*, **538**
**Bone fractures,** Cut off values of bone mineral density defining postmenopausal women with bone fractures, **807**
**Bone marrow,** Persistence of parvovirus B19 in synovial fluid and bone marrow, **597**
**Bone metabolism,** Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis, **556**
**Bone mineral content,** Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis, **193**
**Bone mineral density**
Bone mineral density and bone turnover in spinal osteoarthrosis, **867**
Cut off values of bone mineral density defining postmenopausal women with bone fractures, **807**
Loss of bone mineral density in premenopausal women with systemic lupus erythematosus, **274**
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis, **801**
**Bone turnover,** Bone mineral density and bone turnover in spinal osteoarthrosis, **867**
**Book reviews**
Axford JS, Rees DHE, *editors*. Lyme borreliosis, **800**
Davies ME, Dingle JT, *editors*. The handbook of immunopharmacology, **22**
Duthie RB, Rizza CR, Giangrande PLF, Dodd CAF, *editors*. The management of musculoskeletal problems in the haemophilias, **454**
Eriksen EF, Axelrod DW, Melson F. Bone histomorphometry, **24**
Harries M, Williams C, Stanish W, Micheli L, *editors*. Oxford textbook of sports medicine, **338**
Hughes G. Connective tissue diseases, **89**
Isenberg DA, Horsfall AC, *editors*. Autoimmune disease: focus on Sjögren's syndrome, **707**
Klippel JH, Dieppe PA, editors. Rheumatology, **23**
Maddison PJ, Isenberg DA, Woo P, Glass DN, *editors*. Oxford textbook of rheumatology, **23**
Mandell BF, *editor*. Acute rheumatic and immunological diseases: management of the critically ill patient, **454**
Matsen FA, Lippitt SB, Harryman DT, Sidles JA, *editors*. Practical evaluation and management of the shoulder, **178**
Sergent JS, LeRoy EC, Meenan RF, Panush RS, Reichlin M, *editors*. Year book of rheumatology 1994, **800**
Steering Committee on Future Health Scenarios. Chronic diseases in the year 2005, **866**
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, **548**
Wolfe F, Pincus T, *editors*. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment, **629**
**Bronchial hyperreactivity,** Bronchial hyperreactivity in systemic sclerosis patients: influence of associated Sjögren's syndrome, **636**
**Brown's syndrome,** Brown's syndrome: an important cause of diplopia in systemic lupus erythematosus: *correspondence*, **934**
**Byzantium,** 'Arthritis' in Byzantium (AD 324–1453): unknown information from non-medical literary sources, **951**

**C reactive protein,** Increased C reactive protein is a good predictor of functional outcome in early rheumatoid arthritis, **776** *abst*
**Calcifying pancreatitis,** Chronic calcifying pancreatitis in rheumatic diseases: *correspondence*, **77**
**Calcitonins,** Treatment response in Paget's disease: *leader*, **783**
**Calcium pyrophosphate dihydrate crystals**
Evidence for a causal relationship between the structure, size, and load of calcium pyrophosphate dihydrate crystals, and attacks of pseudogout, **825**
Understanding inorganic pyrophosphate metabolism: toward prevention of calcium pyrophosphate dihydrate crystal deposition: *leader*, **939**
**Calpain,** Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice, **477**
**Cardiovascular functional disorder,** Cardiovascular functional disorder and stress among patients having neck-shoulder symptoms, **494**
**Carpal tunnel syndrome,** Carpal tunnel syndrome as initial manifestation of inflammatory connective tissue diseases: *correspondence*, **782**
**Carrageenan induced arthritis,** Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730, **140**
**Cartilage,** Cartilage metabolism—a response: *matters arising*, **685**
**Cartilage assessment,** Viability of chondroscopy as a means of cartilage assessment: *leader*, **613**
**Cartilage/bone turnover,** Evidence of impaired cartilage/bone turnover inpatients with active ankylosing spondylitis, **556**
**Cartilage degradation**
In vivo model of cartilage degradation—effects of a matrix metalloproteinase inhibitor, **662**
Matrix metalloproteinases and cartilage degradation, **765** *abst*
**Cartilage degrading enzymes,** Cellular basis of rheumatoid joint destruction: expression of oncogenes, adhesion molecules and cartilage degrading enzymes, **524** *abst*
**Cartilage destruction**
Angiostatic steroid or angiogenic heparin treatment results in altered granuloma development and cartilage destruction, **777** *abst*
Cytokine profile dependent on the type of arthritis: dominant role of interleukin-1 in cartilage destruction, **766** *abst*
**Cartilage link protein,** Cellular immunity to cartilage link protein in patients with inflammatory arthritis and non-arthritic controls, **466**
**Cartilage matrix,** Metalloproteinase (MMP) regulation and cartilage matrix loss during granulomatous inflammation in elastase deficient Chediak-Higashi mice, **527** *abst*
**Cartilage thickness,** Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, **263**
**Cathepsin B**
Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage, **289**
Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage, **281**
**CD3-ε,** Signalling by TCRδ/CD3, CD28 and CTLA-4, **763** *abst*
**CD4**
CD4 T cells in the rheumatoid joint are oligoclonally activated and change during the course of disease, **314**
Eicosanoid regulation of human cytotoxic CD4 T cell effector functions, **776** *abst*
Interference with the function of CD4, **762** *abst*
Prostanoid modulation of synovial CD4 T cell cytotoxic function in rheumatoid arthritis, **775** *abst*
**CD4 antibodies,** Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children, **846**
**CD8 lymphocytes,** Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis, **640**
**CD23,** Treatment with antibodies to CD23 markedly ameliorates an established arthritis in DBA/1 mice, **775** *abst*
**CD28**
Interference with the function of CD28, **762** *abst*
Signalling by TCRδ/CD3, CD28 and CTLA-4, **763** *abst*
**CD40 ligand,** Effects of antibodies to the CD40 ligand (gp39) on cell and humoral mediated immunity, **762** *abst*

**CD44,** Expression of CD44 on rheumatoid synovial fluid lymphocytes, **566**
**CD68,** Expression of CD68 synovial fibroblasts in rheumatoid arthritis, **525** *abst*
**Cell adhesion molecules,** Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants, **201**
**Cell death,** Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid, **910**
**Cellular adhesion,** Regulation of cellular adhesion in rheumatoid arthritis by corticosteroids, **765** *abst*
**Cellular immunity,** Cellular immunity to cartilage link protein in patients with inflammatory arthritis and non-arthritic controls, **466**
**Central nervous system,** Controversies in lupus: nervous system involvement: *review*, **159**
**Cervical spine,** A stiff collar can restrict atlantoaxial instability in rheumatoid cervical spine in selected cases, **305**
**Chediak-Higashi mice,** Metalloproteinase (MMP) regulation and cartilage matrix loss during granulomatous inflammation in elastase deficient Chediak-Higashi mice, **527** *abst*
**Chemicals,** Exposure to chemicals and systemic sclerosis: *matters arising*, **529**
**Children,** Imaging the swollen joint in the young patient, **333**
**Chimaeric antibody response,** Human chimaeric antibody response in rheumatoid arthritis patients after treatment with a chimaeric anti-CD4 monoclonal antibody CM-T412, **771** *abst*
**China,** Hip osteoarthritis and dysplasia in Chinese men, **965**
**Chondrocyte IGF-1 receptor,** Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis, **645**
**Chondroitin sulphate,** Immunohistochemical demonstration of fibronectin in the most superficial layer of normal rabbit articular cartilage, **995**
**Chondromalacia,** Proteoglycan depletion and size reduction in lesions of early grade chondromalacia of the patella, **831**
**Chondroscopy,** Viability of chondroscopy as a means of cartilage assessment: *leader*, **613**
**Chronic arthritis**
Parvovirus B19 and chronic arthritis—causal or casual association? *leader*, **535**
Rheumatoid factor, chronic arthritis and mortality, **811**
**Clinical diagnosis,** Comparison of clinical and self reported diagnosis for rheumatology outpatients, **850**
**Clinical studies,** Economic evaluation in rheumatology: a necessity for clinical studies: *leader*, **863**
**Clonal proliferation,** Antibody expression by synovial lymphocytes in rheumatoid arthritis is suggestive of local clonal proliferation, **527** *abst*
**Clonotypes,** CD4 T cells in the rheumatoid joint are oligoclonally activated and change during the course of disease, **314**
**Clq binding,** Synovial hyaluronate in rheumatoid arthritis binds Clq and is covalently bound to antibodies: a model for chronicity, **408**
**Clusters,** Distribution of cases of systemic lupus erythematosus at time of first symptom in an urban area, **891**
***Colchicum autumnale,*** 'Arthritis' in Byzantium (AD 324–1453): unknown information from non-medical literary sources, **951**
**Collagen**
T cell reactivity to human type II collagen, **773** *abst*
T cell recognition of mouse type II collagen in mice, **770** *abst*
**Collagen-induced arthritis**
AP-1 oligonucleotides inhibit collagen-induced arthritis in mice, **524** *abst*
Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice, **477**
Collagen induced arthritis in rhesus monkeys, **760** *abst*
Evaluation of immunological and disease parameters for type II collagen induced arthritis in disease susceptible and resistant rhesus monkeys, **773** *abst*
Inhibition of transfer of collagen induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumour necrosis factor receptor, **768** *abst*
Interleukin-10 treatment inhibits disease progression of mouse collagen induced arthritis, **777** *abst*
Phagocytic lining cells are involved in the onset of collagen type II-induced arthritis, **526** *abst*
Polymorphism in the HLA-DQ locus determines susceptibility and polymorphismin the HLA-DRβ1 genes determine protection in collagen induced arthritis: implications in human rheumatoid arthritis, **760** *abst*
Staphylococcal enterotoxin B increases the severity of type II collagen induced arthritis in mice, **298**
**Collagen metabolism,** Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis, **886**
**Complement factor deficiency,** Homozygous complement factor deficiency and primary antiphospholipid syndrome: a clinical and serological study: *correspondence*, **530**
**Connective tissue diseases,** Carpal tunnel syndrome as initial manifestation of inflammatory connective tissue diseases: *correspondence*, **782**
**Connective tissue syndrome,** Sweet's syndrome associated with undifferentiated connective tissue syndrome: *correspondence*, **937**
**Correction, 78**
**Corticosteroids**
Regulation of cellular adhesion in rheumatoid arthritis by corticosteroids, **765** *abst*
Rheumatoid arthritis, corticosteroid therapy and hip fracture, **49**
**Cost analysis,** Economic evaluation in rheumatology: a necessity for clinical studies: *leader*, **863**
**Coxarthrosis,** Extreme variations in racial rates of total hip arthroplasty for primary coxarthrosis: a population-based study in San Francisco, **107**
**Crystals,** Synovial irritants: crystals, microbes and others—their implications for diagnosis, pathogenesis and therapy, **516**
**CTLA-4,** Signalling by TCRδ/CD3, CD28 and CTLA-4, **763** *abst*
**Cyclo-oxygenases,** Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition: *leader*, **942**
**Cyclosporin**
Cyclosporin A compared with methotrexate in psoriatic arthritis, **776** *abst*
Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis, **137**
Pharmacokinetic profile of a new formulation of cyclosporin in patients with rheumatoid arthritis after conversion from the standard formulation, **774** *abst*
**Cytidine deaminase,** Cytidine deaminase is not released from degranulating polymorphonuclear neutrophils: *correspondence*, **781**
**Cytokine producing cells,** Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis, **525** *abst*, **654**
**Cytokines**
Central role of cytokines in the pathogenesis of autoimmune diseases and the immunotherapy of different autoimmune diseases, especially rheumatoid arthritis, **777** *abst*
Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis, **209**
Cytokine profile dependent on the type of arthritis: dominant role of interleukin-1 in cartilage destruction, **766** *abst*
Cytokine profile is dependent on the type of arthritis, **526** *abst*
Cytokines and cytokine inhibitors: basic principles and clinical perspective, **766** *abst*
Effect of gold treatment on cytokine expression in synovium: *matters arising*, **779**
Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts, **560**
Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines, **382**
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies, **896**
Metalloproteinases, cytokines and angiogenesis, **765** *abst*
Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4, **836**
Therapeutic modulation of cytokines, **519**
Two distinct mechanisms of joint destruction are regulated by different cytokines, **526** *abst*
**Cytoplasmic staining**
Characterisation of anticytoplasmic antibodies and their clinical associations, **269**
Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases: *matters arising*, **779**
**Cytotoxic T lymphocyte activity,** Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies: *leader*, **329**

**Degenerative spondylolisthesis,** Sciatica in degenerative spondylolisthesis of the lumbar spine, **539**
**Dermatomyositis,** Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis: *correspondence*, **607**
**Destructive large joint arthritis,** Destructive large joint arthritis: *lesson of the month*, **626**

**Diabetes mellitus**
Microalbuminuria is associated with limited joint mobility in type I diabetes mellitus, **582**
Vertebral hyperostosis and diabetes mellitus, **375**
**Diagnosis,** Comparison of clinical and self reported diagnosis for rheumatology outpatients, **850**
**Diclofenac,** Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac and hyaluronan induced targeting technology, **766** *abst*
**Diplopia,** Brown's syndrome: an important cause of diplopia in systemic lupus erythematosus: *correspondence*, **934**
**Disability,** Association of locomotor complaints and disability in the Rotterdam study, **721**
**Disc degeneration,** Human lumbar apophyseal joint damage and intervertebral disc degeneration, **182**
**Disease duration,** Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies, **69**
**Drug discontinuation analyses,** Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients, **708**
**Drugs,** Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis?, **948**
**Dual energy x ray absorption scans,** Early rheumatoid arthritis: time to aim for remission?, **944**
**DXA scans,** Early rheumatoid arthritis: time to aim for remission?, **944**
**Dysplasia,** Hip osteoarthritis and dysplasia in Chinese men, **965**
**Dyspnoea,** Causes and investigation of increasing dyspnoea in rheumatoid arthritis, **17**

**Early rheumatoid arthritis,** Early rheumatoid arthritis: time to aim for remission?, **944**
**Economic evaluation,** Economic evaluation in rheumatology: a necessity for clinical studies: *leader*, **863**
**Ectopeptidases,** Expression of ectopeptidases in scleroderma, **111**
**Education,** Rheumatology education and management skills in general practice: a national study of trainees, **735**
**Eicosanoid regulation,** Eicosanoid regulation of human cytotoxic CD4 T cell effector functions, **776** *abst*
**Elderly,** Wegener's granulomatosis of the elderly: a case report of uncommon severe gangrene of the feet: *correspondence*, **328**
**Electron spin resonance spectroscopy,** Electron spin resonance spectroscopic demonstration of the generation of reactive oxygen species by diseased human synovial tissue following ex vivo hypoxia-reoxygenation, **94**
**Endocrine disorders,** Endocrine disorders in rheumatoid arthritis, **772** *abst*
**Endogenous cyclo-oxygenase product,** Influence of endogenous cyclo-oxygenase product(s) on synovial fibroblast cultures, **528** *abst*
**Endothelial cells,** Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus, **361**
**Endothelin-1**
Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus, **361**
Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension, **730**
**Eosinophilia myalgia syndrome,** Antineutrophil cytoplasmic antibodies and the eosinophilia myalgia syndrome: *correspondence*, **233**
***Escherichia coli,*** Decrease in anti-*Proteus mirabilis* but not anti-*Escherichia coli* antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet, **221**
**Exercise,** Exercise in primary prevention of osteoporosis in women: *leader*, **861**
**Experimental autoimmune encephalomyelitis,** Prevention and treatment of experimental autoimmune encephalomyelitis using non-cytotoxic anti-class II MHC antibodies, **762** *abst*
**Experimentally induced arthritis,** Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis, **645**
**Extracellular matrix**
Extracellular matrix of the synovial intimal cell layer, **404**
Interaction between synoviocytes and extracellular matrix in vitro, **413**
**Extractable nuclear antigen,** Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases: *matters arising*, **779**

**Factor V Arg 506 → Gln mutation,** Activated protein C resistance caused by factor V Arg 506 → Gln mutation has no role in thrombotic manifestations of Behçet's disease: *correspondence*, **860**
**Fcγ receptors,** Expression of Fcγ receptors on synovial fluid neutrophils and activation by soluble immune complexes, **778** *abst*
**Femoral head cartilage**
Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage, **289**
Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage, **281**
**Fibroblasts**
Expression of CD68 synovial fibroblasts in rheumatoid arthritis, **525** *abst*
Synovial intimal fibroblasts, **395**
**Fibromyalgia**
Fibromyalgia: why such controversy? *leader*, **3**
The semeiology of arthritis: discriminating between patients on the basis of their symptoms, **924**
**Fibronectin**
Immunohistochemical demonstration of fibronectin in the most superficial layer of normal rabbit articular cartilage, **995**
Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus, **117**
**Flow cytometry,** What you need to know when you go with the flow: pitfalls in the use of flow cytometry: *leader*, **785**
**France,** Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France, **587**

**Gallium-67 citrate scintigraphy,** Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis, **856**
**Gangrene,** Wegener's granulomatosis of the elderly: a case report of uncommon severe gangrene of the feet: *correspondence*, **328**
**Gd-DTPA**
Intravenous Gd-DTPA enhancement of joint fluid on magnetic resonance imaging: a measurement of trans-synovial flow?, **435** *abst*
Measurement of synovial volume and rates of synovial enhancement with Gd-DTPA enhanced magnetic resonance imaging, **435** *abst*
**Gender difference,** Why the gender difference in susceptibility to rheumatoid arthritis? *leader*, **694**
**Gene therapy,** Gene therapy for arthritis, **769** *abst*
**Gene transcription,** Regulation of gene transcription by glucocorticoids, **766** *abst*
**General practice**
Rheumatology education and management skills in general practice: a national study of trainees, **735**
Shoulder disorders in general practice: incidence, patient characteristics, and management, **959**
**Giant cell arteritis,** Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis, **640**
**Glossary,** Commented glossary for rheumatic spinal diseases, based on pathology, **615**
**Glucocorticoids**
Regulation of gene transcription by glucocorticoids, **766** *abst*
Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses: *review*, **6**
**Glycosaminoglycan,** Glycosaminoglycan concentration in rabbit synovium and its relation to pressure induced increased permeability, **435** *abst*
**Glycosylation,** Does it take sugar? A clinical role for measuring the glycosylation of IgG: *leader*, **689**
**Gold therapy,** Effect of long term intramuscular gold therapy on the seroprevalence of *Helicobacter pylori* in patients with early rheumatoid arthritis: *correspondence*, **437**
**Gold treatment,** Effect of gold treatment on cytokine expression in synovium: *matters arising*, **779**
**Gout**
Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia, **351**
'Arthritis' in Byzantium (AD 324–1453): unknown information from non-medical literary sources, **951**
Gout: questions that still need to be answered: *leader*, **79**
Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout, **90**
Missed opportunity following diagnosis of gout: *lesson of the month*, **86**
**Granuloma,** Angiostatic steroid or angiogenic heparin treatment results in altered granuloma development and cartilage destruction, **777** *abst*
**Granulomatous inflammation**
Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac and hyaluronan induced targeting technology, **766** *abst*

Metalloproteinase (MMP) regulation and cartilage matrix loss during granulomatous inflammation in elastase deficient Chediak-Higashi mice, **527** *abst*

**Granulomatous tissue,** Regression of granulomatous tissue neovasculature with angiostatic steroid therapy, **777** *abst*

**Granulomatous vasculitis,** Pregnancy in granulomatous vasculitis, **604**

**Haematological diseases,** Rheumatological manifestations of haematological diseases: *review*, **787**

**Haematuria,** Mechanism of haematuria in lupus nephritis: *correspondence*, **934**

**Haemochromatosis,** Rheumatological manifestations of haematological diseases: *review*, **787**

**Haemophilias,** Rheumatological manifestations of haematological diseases: *review*, **787**

**Health Assessment Questionnaire,** Ceiling effects of the Health Assessment Questionnaire and its modified version in some ambulatory rheumatoid arthritis patients, **461**

**Heat shock protein,** Antibody to *Mycobacterium tuberculosis* 65 kDa heat shock protein in patients with rheumatoid arthritis, **225**

**Heat shock protein 60,** Autoreactivity to human heat shock protein 60 predicts disease remission in oligoarticular juvenile chronic arthritis, **775** *abst*

**Heat shock protein 65,** PPD and hsp65 induced monoarthritis initiates spontaneous recurrent flares in Lewis rats, **59**

***Helicobacter pylori*,** Effect of long term intramuscular gold therapy on the seroprevalence of *Helicobacter pylori* in patients with early rheumatoid arthritis: *correspondence*, **437**

**Hemiparesis,** Asymmetrical nodular osteoarthritis in a patient with a hemiparesis: *correspondence*, **936**

**Hemiplegia,** Asymmetric rheumatoid vasculitis in a hemiplegic patient: *correspondence*, **532**

**Heparin,** Angiostatic steroid or angiogenic heparin treatment results in altered granuloma development and cartilage destruction, **777** *abst*

***Herpes zoster*,** Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate: *matters arising*, **155**

**High resolution computed tomography**

Causes and investigation of increasing dyspnoea in rheumatoid arthritis, **17**

High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis, **308**

Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis, **815**

**Hip**

Hip involvement in early rheumatoid arthritis, **45**

Hip osteoarthritis and dysplasia in Chinese men, **965**

Osteoarthritis of the hip joint and acetabular dysplasia in women, **179**

**Hip fracture,** Rheumatoid arthritis, corticosteroid therapy and hip fracture, **49**

**Hip replacement,** Extreme variations in racial rates of total hip arthroplasty for primary coxarthrosis: a population-based study in San Francisco, **107**

**HIV infection,** Relapsing polychondritis and Behçet's syndrome in a patient with HIV infection: *correspondence*, **780**

**HIV-1 infection,** Does rheumatoid arthritis improve after HIV-1 infection? A case report, **774** *abst*

**HLA associations,** HLA associations of systemic lupus erythematosus in Chinese from Singapore: *correspondence*, **687**

**HLA-B7,** Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7, **125**

**HLA-B27**

Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice, **754**

Might patients with HLA-B27 related diseases benefit from antiandrogenic treatment? *correspondence*, **531**

Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis, **321**

Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies: *leader*, **329**

**HLA class II antigens,** HLA class II antigens associated with systemic lupus erythematosus in black South Africans, **678**

**HLA class II genes,** HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), **983**

**HLA-DQ locus,** Polymorphism in the HLA-DQ locus determines susceptibility and polymorphism in the HLA-DRβ1 genes determine protection in collagen induced arthritis: implications in human rheumatoid arthritis, **760** *abst*

**HLA-DQB1,** TAP polymorphism in patients with Behçet's disease, **386**

**HLA-DR alleles,** Lack of influence of non-inherited maternal HLA-DR alleles on susceptibility to rheumatoid arthritis, **311**

**HLA-DR4,** Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association, **775** *abst*

**HLA-DRB1*0405,** Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis, **988**

**HLA system,** Autosomal dominant undifferentiated spondyloarthropathy not related to the HLA system: *matters arising*, **686**

**Hodgkin's lymphoma,** Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis: *correspondence*, **607**

**166Holmium-hydroxylapatite,** Effects of 166holmium-hydroxylapatite beads on the synovium of the antigen induced arthritis rabbit stifle, **525** *abst*

**Human parvovirus B19 infection,** Association between human parvovirus B19 infection and arthritis, **498**

**Hyaluronan**

Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac and hyaluronan induced targeting technology, **766** *abst*

Effect of synovial fluid hyaluronan on the clearance of albumin from the canine knee, **433**

Functions of hyaluronan, **429**

Histochemical localisation of hyaluronan in healthy and diseased cartilage of knee joints, **435** *abst*

Hyaluronan synthesis in joint cavitation, **435** *abst*

**Hybridoma,** Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus, **471**

**Hydroxyapatite,** Radiation synovectomy using particulate hydroxyapatite as the vehicle for a therapeutic radionuclide, **528** *abst*

**Hyperlipidaemia,** Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients: *correspondence*, **609**

**Hypertension,** Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension, **730**

**Hypertriglyceridaemia,** Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia, **351**

**Hyperuricaemia,** Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients: *correspondence*, **609**

**Hypoxia-reoxygenation,** Electron spin resonance spectroscopic demonstration of the generation of reactive oxygen species by diseased human synovial tissue following ex vivo hypoxia-reoxygenation, **94**

**Illness behaviour,** Illness behaviour in patients with arthritis, **245**

**Iloprost,** Oral iloprost as a treatment for Raynaud's syndrome, **197**

**Immunoglobulin A**

Ankylosing spondylitis, IgA, and transforming growth factors: *hypothesis*, **544**

Clinical implications of IgA rheumatoid factor subclasses, **578**

**Immunoglobulin A subclass antibodies,** IgA1 and IgA2 subclass antibodies against *Klebsiella pneumoniae* in the sera of patients with peripheral and axial types of ankylosing spondylitis, **631**

**Immunoglobulin E,** Increased serum IgE level and interleukin-4 release from cultured lymphocytes from a patient with adult onset Still's disease, **752**

**Immunoglobulin G,** Does it take sugar? A clinical role for measuring the glycosylation of IgG: *leader*, **689**

**Immunoglobulin G4,** Biological effects of a human IgG4 monoclonal antibody in vivo, **774** *abst*

**Immunoglobulin M antibody,** Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis, **713**

**Immunoglobulins**

Clinical and histological aspects of intravenous immunoglobulin treatment of systemic lupus erythematosus, **770** *abst*

Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines, **382**

Successful application of high dose intravenous immunoglobulins in Sjögren's syndrome associated arthritis: *correspondence*, **936**

**Immunophilin,** Immunophilin binding drugs, **764** *abst*

**Immunotherapy,** Third International Symposium on the Immunotherapy of the Rheumatic Diseases, Cyprus, May 1995, introduction and overview, **757** abstracts, **759**

**Inflammation,** Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid, **33**

**Inflammatory arthritis,** Cellular immunity to cartilage link protein in patients with inflammatory arthritis and non-arthritic controls, **466**

**Inflammatory erosive joint disease,** Zymosan arthritis: a model of inflammatory erosive joint disease, **527** *abst*
**Inflammatory joint disease,** Oxygen radicals, nitric oxide and human inflammatory joint disease, **505**
**Inflammatory macrophages,** Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants, **201**
**Inflammatory myopathy**
Respiratory chain enzyme defects in patients with idiopathic inflammatory myopathy, **491**
Serum myosin light chain determinations in patients with inflammatory myopathy—a preliminary report: *correspondence*, **608**
**Innervation,** Innervation of the synovium, **398**
**Insulin-like growth factor 1**
Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis, **645**
IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints, **976**
**Intercellular adhesion molecule-1,** Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts, **560**
**Interleukin-1**
Cytokine profile dependent on the type of arthritis: dominant role of interleukin-1 in cartilage destruction, **766** *abst*
IL-1 and IL-1ra production by different macrophage subsets in rheumatoid arthritis synovial membranes, **771** *abst*
IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints, **976**
Interleukin-1 expression by neutrophils in rheumatoid arthritis, **930**
Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells, **484**
Transgenic analyses of the role of tumour necrosis factor and interleukin-1 in arthritis, **767** *abst*
**Interleukin-1 receptor,** Recombinant human soluble interleukin-1 receptor as potential treatment for rheumatoid arthritis, **769** *abst*
**Interleukin-1 receptor antagonist**
Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis, **591**
Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis, **318**
**Interleukin-2 receptor,** Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis, **640**
**Interleukin-4**
Increased serum IgE level and interleukin-4 release from cultured lymphocytes from a patient with adult onset Still's disease, **752**
Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4, **836**
**Interleukin-6**
Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study, **674**
Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis, **137**
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid, **33**
**Interleukin-8,** Serum levels of interleukin-8 in patients with Behçet's disease: *correspondence*, **610**
**Interleukin-10,** Interleukin-10 treatment inhibits disease progression of mouse collagen induced arthritis, **777** *abst*
**Interstitial collagenase (MMP-1),** Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis, **970**
**Intervertebral disc degeneration,** Human lumbar apophyseal joint damage and intervertebral disc degeneration, **182**
**Intra-articular pressure**
Feeling the pressure: *leader*, **611**
Intra-articular pressure changes in rheumatoid and normal peripheral joints, **670**
**Intravenous immunoglobulins,** Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines, **382**
**Irritable hip,** Teenager with an irritable hip, anaemia and malaise: *masterclass*, **701**
**Japan,** HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), **983**
**Joint complaints,** Association of locomotor complaints and disability in the Rotterdam study, **721**
**Joint destruction,** Two distinct mechanisms of joint destruction are regulated by different cytokines, **526** *abst*
**Joint mobility,** Microalbuminuria is associated with limited joint mobility in type I diabetes mellitus, **582**
**Joint pressure**
Feeling the pressure: *leader*, **611**
Intra-articular pressure changes in rheumatoid and normal peripheral joints, **670**
**Joint replacements,** Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants, **201**
**Joint space width,** Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, **263**
**Joint space width measurements,** Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees, **872**
**Joints**
Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice, **477**
Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules, **417**
Histochemical localisation of hyaluronan in healthy and diseased cartilage of knee joints, **435** *abst*
Hyaluronan synthesis in joint cavitation, **435** *abst*
Imaging the swollen joint in the young patient, **333**
Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis, **528** *abst*
Localisation of latex particles in the rat knee joint, **436** *abst*
**Juvenile chronic arthritis (juvenile rheumatoid arthritis)**
Antiperinuclear factor in the polyarticular form of juvenile chronic arthritis: are use of frozen material or age of patients relevant? *matters arising*, **76**
Autoreactivity to human heat shock protein 60 predicts disease remission in oligoarticular juvenile chronic arthritis, **775** *abst*
Imaging the swollen joint in the young patient, **333**
Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis, **193**
Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children, **846**

**Kallikrein,** Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis, **345**
**68 kDa autoantigen,** Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies, **355**
**52 kDa Ro(SS-A) antigen,** Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNFα, **904**
**Keratinocytes,** Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNFα, **904**
***Klebsiella pneumoniae,*** IgA1 and IgA2 subclass antibodies against *Klebsiella pneumoniae* in the sera of patients with peripheral and axial types of ankylosing spondylitis, **631**
**Knee**
Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees, **872**
Factors affecting radiographic progression of knee osteoarthritis, **53**
Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response, **379**
Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, **263**
**Knee joint**
Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice, **477**
Effect of synovial fluid hyaluronan on the clearance of albumin from the canine knee, **433**
Histochemical localisation of hyaluronan in healthy and diseased cartilage of knee joints, **435** *abst*
IL-1 has no direct role in the IGF-1 non-responsive state during experimentally induced arthritis in mouse knee joints, **976**
Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis, **528** *abst*
Localisation of latex particles in the rat knee joint, **436** *abst*
**Knee joint synovitis,** Prospective sonographic and arthroscopic evaluation of proliferative knee joint synovitis, **771** *abst*

**Korea,** Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis, **988**

**Labial salivary glands,** Transforming growth factor β2 in labial salivary glands in Sjögren's syndrome, **744**
**Lapine monoarticular arthritis,** Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis, **591**
**Large joint arthritis,** Destructive large joint arthritis: *lesson of the month*, **626**
**La(SS-B) antigen,** Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNFα, **904**
**Latex particles,** Localisation of latex particles in the rat knee joint, **436** *abst*
**Leflunomide,** Phase II clinical trials with leflunomide in rheumatoid arthritis, **764** *abst*
**Leucocyte antigen,** Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome: *correspondence*, **780**
**Leukaemia(s)**
Rheumatological manifestations of haematological diseases: *review*, **787**
Secondary acute myeloid leukaemia with 7q– complicating azathioprine treatment for rheumatoid arthritis: *correspondence*, **155**
**Lipoprotein,** Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout, **90**
**LMP2 gene,** Polymorphism in the LMP2 gene influences susceptibility to extraspinal disease in HLA-B27 positive individuals with ankylosing spondylitis, **321**
**Locomotor complaints,** Association of locomotor complaints and disability in the Rotterdam study, **721**
**Long term outcome,** Early rheumatoid arthritis: time to aim for remission?, **944**
**Low back pain,** Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain, **100**
**Low calorie diet,** Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients: *correspondence*, **609**
**Lp(a) lipoprotein levels,** Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease, **726**
**Lumbar apophyseal joint damage,** Human lumbar apophyseal joint damage and intervertebral disc degeneration, **182**
**Lumbar spine,** Sciatica in degenerative spondylolisthesis of the lumbar spine, **539**
**Lungs**
High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis, **308**
Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis, **815**
**Lupus nephritis,** Mechanism of haematuria in lupus nephritis: *correspondence*, **934**
**Lymphocyte migration,** Radiolabelled lymphocyte migration in rheumatoid synovitis, **39**
**Lymphocytes,** Expression of CD44 on rheumatoid synovial fluid lymphocytes, **566**
**Lymphoma**
Defective repair of $O^6$-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma, **229**
Rheumatological manifestations of haematological diseases: *review*, **787**
**Lymphoproliferative malignancy,** Rheumatological manifestations of haematological diseases: *review*, **787**

**Macrophages**
Lack of causal relationship between inducibility/severity of adjuvant arthritis in the rat and disease associated changes in production of nitric oxide by macrophages, **325**
Radiological progression in rheumatoid arthritis relates to macrophage population in the synovium, **526** *abst*
Synovial macrophages, **392**
**Macrovascular disease,** Increased prevalence of symptomatic macrovascular disease in systemic sclerosis, **853**
**Magic bullet,** Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis?, **948**
**Magnesium whitlockite,** Magnesium whitlockite deposition in articular cartilage: a study of 80 specimens from 70 patients, **339**
**Magnetic resonance imaging**
Intravenous Gd-DTPA enhancement of joint fluid on magnetic resonance imaging: a measurement of trans-synovial flow?, **435** *abst*
Measurement of synovial volume and rates of synovial enhancement with Gd-DTPA enhanced magnetic resonance imaging, **435** *abst*
Osteoarthritis and magnetic resonance imaging: potential and problems: *review*, **237**
**Malaise,** Teenager with an irritable hip, anaemia and malaise: *masterclass*, **701**
**Management skills,** Rheumatology education and management skills in general practice: a national study of trainees, **735**
**Mast cells**
Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion, **549**
Mast cells and matrix degradation at the rheumatoid lesion, **525** *abst*
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies, **896**
Mast cells in the rheumatoid lesion—ringleaders or innocent bystanders? *leader*, **533**
**Maternal age,** Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice, **754**
**Matrix degradation,** Mast cells and matrix degradation at the rheumatoid lesion, **525** *abst*
**Matrix metalloproteinase inhibitor,** In vivo model of cartilage degradation—effects of a matrix metalloproteinase inhibitor, **662**
**Matrix metalloproteinases**
Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis, **25**
Immunolocalisation studies on six matrix metalloproteinases, TIMP-1, and TIMP-2 in synovia from arthritic joints, **527** *abst*
Metalloproteinase (MMP) regulation and cartilage matrix loss during granulomatous inflammation in elastase deficient Chediak-Higashi mice, **527** *abst*
**Mesenchymal reaction,** Mesenchymal reaction, **764** *abst*
**Metalloproteinases**
Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis, **970**
Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases, **571**
In vivo model of cartilage degradation—effects of a matrix metalloproteinase inhibitor, **662**
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies, **896**
Matrix metalloproteinases and cartilage degradation, **765** *abst*
Metalloproteinases, cytokines and angiogenesis, **765** *abst*
**Metastasis,** Synovial joints are immune to metastasis, **436** *abst*
**Methotrexate**
Cyclosporin A compared with methotrexate in psoriatic arthritis, **776** *abst*
Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis: *correspondence*, **607**
Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate: *matters arising*, **155**
Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients, **708**
**Microalbuminuria**
Microalbuminuria is associated with limited joint mobility in type I diabetes mellitus, **582**
Microalbuminuria in patients with rheumatoid arthritis, **189**
**Misoprostol,** Experience with misoprostol therapy for NSAID gastropathy in children, **277**
**Mitochondrial dysfunction,** Respiratory chain enzyme defects in patients with idiopathic inflammatory myopathy, **491**
**Monoarthritis,** PPD and hsp65 induced monoarthritis initiates spontaneous recurrent flares in Lewis rats, **59**
**Monoarticular arthritis,** Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis, **591**
**Monoclonal antibody(ies)**
Biological effects of a human IgG4 monoclonal antibody in vivo, **774** *abst*
Human chimaeric antibody response in rheumatoid arthritis patients after treatment with a chimaeric anti-CD4 monoclonal antibody CM-T412, **771** *abst*
Long term follow up of patients with active rheumatoid arthritis injected with murine idiotypic class II monoclonal antibodies, **771** *abst*
Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies, **366**
**Monoclonal autoantibodies,** Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus, **471**
**Mortality,** Rheumatoid factor, chronic arthritis and mortality, **811**
**Multiple myeloma,** Rheumatological manifestations of haematological diseases: *review*, **787**

**Muscular dystrophy(ies),** New questions about the muscular dystrophies: *leader,* **536**
**Musculoskeletal pain,** Different concepts of chronic musculoskeletal pain: *leader,* **331**: *matters arising,* **859**
***Mycobacterium tuberculosis,*** Antibody to *Mycobacterium tuberculosis* 65 kDa heat shock protein in patients with rheumatoid arthritis, **225**
**Myopathy,** Serum myosin light chain determinations in patients with inflammatory myopathy—a preliminary report: *correspondence,* **608**
**Myosin light chain,** Serum myosin light chain determinations in patients with inflammatory myopathy—a preliminary report: *correspondence,* **608**

**Nail fold vasculitis,** Isolated nail fold vasculitis in rheumatoid arthritis, **927**
**Nasal tolerance,** Nasal tolerance, **761** *abst*
**Natural killer cells,** Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies, **69**
**Neck-shoulder symptoms,** Cardiovascular functional disorder and stress among patients having neck-shoulder symptoms, **494**
**Neovascularisation,** Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants, **201**
**Neutrophils**
Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis, **916**
Expression of Fcγ receptors on synovial fluid neutrophils and activation by soluble immune complexes, **778** *abst*
Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid, **910**
Interleukin-1 expression by neutrophils in rheumatoid arthritis, **930**
**Nimesulide,** Nimesulide, a sulphonanilide non-steroidal anti-inflammatory drug, inhibits mediator release from human synovial mast cells, **775** *abst*
**Nitrate excretion,** Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone, **820**
**Nitric oxide**
Lack of causal relationship between inducibility/severity of adjuvant arthritis in the rat and disease associated changes in production of nitric oxide by macrophages, **325**
Oxygen radicals, nitric oxide and human inflammatory joint disease, **505**
Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone, **820**
**Nodules,** Subcutaneous nodules in a patient with polyarthritis: *lesson of the month,* **796**
**Non-obese diabetic mouse model,** The NOD mouse model—the development of strategies to treat human autoimmune disease, **759** *abst*
**Non-steroidal anti-inflammatory drugs**
Experience with misoprostol therapy for NSAID gastropathy in children, **277**
Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition: *leader,* **942**
**Notes/News, 22, 88, 177, 244, 337, 453, 547, 628, 706, 798, 865, 958**

***O*$^6$-methylguanine-DNA,** Defective repair of *O*$^6$-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma, **229**
**Oligonucleotides,** AP-1 oligonucleotides inhibit collagen-induced arthritis in mice, **524** *abst*
**Oncogenes,** Cellular basis of rheumatoid joint destruction: expression of oncogenes, adhesion molecules and cartilage degrading enzymes, **524** *abst*
**Oral tolerance**
Oral tolerance in autoimmune diseases, **761** *abst*
Results of a German study of oral tolerance, **761** *abst*
**Orthopaedic implants,** Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants, **201**
**Osteoarthritis**
Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees, **872**
Asymmetrical nodular osteoarthritis in a patient with a hemiparesis: *correspondence,* **936**
Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage, **289**
Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage, **281**
Clinical implications of osteoarthritis and ageing: *review,* **82**
Factors affecting radiographic progression of knee osteoarthritis, **53**
Hip osteoarthritis and dysplasia in Chinese men, **965**
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis, **345**
Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis, **25**
Instruments to assess osteoarthritis—current status and future needs: *leader,* **692**
Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis, **318**
Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response, **379**
Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, **263**
Osteoarthritis and magnetic resonance imaging: potential and problems: *review,* **237**
Osteoarthritis of the hip joint and acetabular dysplasia in women, **179**
Physicochemical properties of human synovial effusions in osteoarthritis patients discontinued from anti-inflammatory medication, **527** *abst*
Role of molecular markers in the diagnosis and treatment of osteoarthritis, **524** *abst*
Skeletal evidence of osteoarthritis: a palaeopathological perspective, **443**
Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis, **144**
**Osteocalcin,** Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis, **193**
**Osteoclast markers,** Multinucleate cells in pigmented villonodular synovitis express osteoclast markers, **436** *abst*
**Osteopenia,** Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells, **484**
**Osteoporosis**
Exercise in primary prevention of osteoporosis in women: *leader,* **861**
Osteoporosis in rheumatological practice: questions to be answered: *leader,* **1**
Progressive shoulder arthropathy, **168**
Steroid induced osteoporosis: an opportunity for prevention?, **66**
**Outcome**
Clinical and radiological outcome measures, **769** *abst*
Prognosis features and outcome of early rheumatoid arthritis, **770** *abst*
**Outpatients,** Comparison of clinical and self reported diagnosis for rheumatology outpatients, **850**
**Oxidative response,** Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis, **916**
**Oxygen radicals,** Oxygen radicals, nitric oxide and human inflammatory joint disease, **505**

**$P_i$ antigen,** Similar anti-*Proteus mirabilis* titres in $P_i$ positive and $P_i$ negative individuals with rheumatoid arthritis: *matters arising,* **607**
**p80 fusion protein,** Treatment of rheumatoid arthritis with recombinant soluble tumour necrosis factor receptor p80 fusion protein, **767** *abst*
**Paget's disease,** Treatment response in Paget's disease: *leader,* **783**
**Pain,** Different concepts of chronic musculoskeletal pain: *leader,* **331**: *matters arising,* **859**
**Pamidronate,** Treatment of refractory reflex sympathetic dystrophy with pamidronate: *correspondence,* **687**
**Pancreatitis,** Chronic calcifying pancreatitis in rheumatic diseases: *correspondence,* **77**
**Paraplegia,** Paraplegia with sclerotic vertebral lesions: *lesson of the month,* **20**
**Parvovirus B19**
Parvovirus B19 and chronic arthritis—causal or casual association? *leader,* **535**
Persistence of parvovirus B19 in synovial fluid and bone marrow, **597**
**Patella,** Proteoglycan depletion and size reduction in lesions of early grade chondromalacia of the patella, **831**
**Pathogenesis,** Pathogenesis of rheumatoid arthritis: an overview, **759** *abst*
**Penicillamine,** Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis: *correspondence,* **529**

**Pentoxifylline,** Thalidomide and pentoxifylline in rheumatoid arthritis: preliminary results of an open study, 773 *abst*
**Peptide binding,** Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association, 775 *abst*
**Periarticular osteopenia,** Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells, 484
**Pericardial tamponade,** Pericardial tamponade preceding cutaneous involvement in systemic sclerosis: *correspondence*, 687
**Peripheral arthritis,** Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis, 128
**Phagocytic lining cells,** Phagocytic lining cells are involved in the onset of collagen type II-induced arthritis, 526 *abst*
**Phospholipid binding specificities,** Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus, 471
**Photodynamic treatment,** Photodynamic treatment of antigen induced arthritis in rabbits, 776 *abst*
**Pigmented villonodular synovitis,** Multinucleate cells in pigmented villonodular synovitis express osteoclast markers, 436 *abst*
**Pitting oedema,** Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome?, 681
**Platelet activating factor antagonist,** Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730, 140
**Pneumocystis carinii pneumonia,** Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis, 991
**Polyarteritis nodosa,** Benign cutaneous polyarteritis nodosa in children below 10 years of age—a clinical experience, 134
**Polyarthritis**
*Proteus*—is it a likely aetiological factor in chronic polyarthritis? *leader*, 157
Subcutaneous nodules in a patient with polyarthritis: *lesson of the month*, 796
**Polyarticular form of juvenile chronic arthritis,** Antiperinuclear factor in the polyarticular form of juvenile chronic arthritis: are use of frozen material or age of patients relevant? *matters arising*, 76
**Polychondritis,** Relapsing polychondritis and Behçet's syndrome in a patient with HIV infection: *correspondence*, 780
**Polymorphism,** Polymorphism in the HLA-DQ locus determines susceptibility and polymorphism in the HLA-DRβ1 genes determine protection in collagen induced arthritis: implications in human rheumatoid arthritis, 760 *abst*
**Polymorphonuclear neutrophils,** Cytidine deaminase is not released from degranulating polymorphonuclear neutrophils: *correspondence*, 781
**Polymyalgia rheumatica,** Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis, 640
**Polymyositis,** Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome: *correspondence*, 780
**Postmenopausal women,** Cut off values of bone mineral density defining postmenopausal women with bone fractures, 807
**Prediction of outcome,** Early rheumatoid arthritis: time to aim for remission?, 944
**Prednisolone,** Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone, 820
**Pregnancy,** Pregnancy in granulomatous vasculitis, 604
**Premenopause,** Loss of bone mineral density in premenopausal women with systemic lupus erythematosus, 274
**Primary biliary cirrhosis,** Specificity of antinuclear antibodies in primary biliary cirrhosis, 148
**Procollagenase,** Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases, 571
**Prostaglandins,** Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition: *leader*, 942
**Prostanoid modulation,** Prostanoid modulation of synovial CD4 T cell cytotoxic function in rheumatoid arthritis, 775 *abst*
**Protein kinase C inhibitors,** Protein kinase C inhibitors, 763 *abst*
**Proteoglycans,** Proteoglycan depletion and size reduction in lesions of early grade chondromalacia of the patella, 831
***Proteus,*** *Proteus*—is it a likely aetiological factor in chronic polyarthritis? *leader*, 157
***Proteus mirabilis***
Decrease in anti-*Proteus mirabilis* but not anti-*Escherichia coli* antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet, 221
Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and *Proteus mirabilis* in rheumatoid arthritis, 216
Similar anti-*Proteus mirabilis* titres in $P_1$ positive and $P_1$ negative individuals with rheumatoid arthritis: *matters arising*, 607
**Pseudogout,** Evidence for a causal relationship between the structure, size, and load of calcium pyrophosphate dihydrate crystals, and attacks of pseudogout, 825
**Psoriatic arthritis**
Cyclosporin A compared with methotrexate in psoriatic arthritis, 776 *abst*
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis, 345
**Purified protein derivative,** PPD and hsp65 induced monoarthritis initiates spontaneous recurrent flares in Lewis rats, 59
**Pyrexial illness,** Beware the steroid responsive nature of a pyrexial illness: *lesson of the month*, 451
**Pyridinium,** Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis, 144
**Pyridinium crosslinks,** Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis, 556
**Pyrophosphate metabolism,** Understanding inorganic pyrophosphate metabolism: toward prevention of calcium pyrophosphate dihydrate crystal deposition: *leader*, 939

**Quality of life,** Quality of life—a measure too far? *leader*, 439

**Radiation synovectomy,** Radiation synovectomy using particulate hydroxyapatite as the vehicle for a therapeutic radionuclide, 528 *abst*
**Raynaud's syndrome,** Oral iloprost as a treatment for Raynaud's syndrome, 197
**Reactive arthritis,** *Staphylococcus aureus* triggered reactive arthritis, 131
**Reactive oxygen species,** Electron spin resonance spectroscopic demonstration of the generation of reactive oxygen species by diseased human synovial tissue following ex vivo hypoxia-reoxygenation, 94
**Reflex sympathetic dystrophy,** Treatment of refractory reflex sympathetic dystrophy with pamidronate: *correspondence*, 687
**Remission,** Early rheumatoid arthritis: time to aim for remission?, 944
**Remitting seronegative symmetrical synovitis,** Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome?, 681
**Respiratory chain enzyme defects,** Respiratory chain enzyme defects in patients with idiopathic inflammatory myopathy, 491
**Retroviruses,** Retroviruses in rheumatic diseases: *leader*, 441
**Rheumatic diseases**
Chronic calcifying pancreatitis in rheumatic diseases: *correspondence*, 77
Cytoplasmic staining, ANA negative status, and ENA testing in rheumatic diseases: *matters arising*, 779
Third International Symposium on the Immunotherapy of the Rheumatic Diseases, Cyprus, May 1995, abstracts, 757
**Rheumatic fever,** Rheumatic fever: autoantibodies against a variety of cardiac, nuclear, and streptococcal antigens, 740
**Rheumatic spinal diseases,** Commented glossary for rheumatic spinal diseases, based on pathology, 615
**Rheumatoid arthritis**
A tumour necrosis factor α polymorphism is not associated with rheumatoid arthritis, 601
Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis: *correspondence*, 529
Activation of synovial fibroblasts in rheumatoid arthritis, 501
Antibody expression by synovial lymphocytes in rheumatoid arthritis is suggestive of local clonal proliferation, 527 *abst*
Antibody to *Mycobacterium tuberculosis* 65 kDa heat shock protein in patients with rheumatoid arthritis, 225
Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis, 886
Assessment of cutaneous sensory and autonomic axon reflexes in rheumatoid arthritis, 251
Autoantigens in rheumatoid arthritis, 759 *abst*
Biochemical measurement of disease activity, 770 *abst*
Causes and investigation of increasing dyspnoea in rheumatoid arthritis, 17
Ceiling effects of the Health Assessment Questionnaire and its modified version in some ambulatory rheumatoid arthritis patients, 461
Central role of cytokines in the pathogenesis of autoimmune diseases and the immunotherapy of different autoimmune diseases, especially rheumatoid arthritis, 777 *abst*

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study, **674**
Decrease in anti-*Proteus mirabilis* but not anti-*Escherichia coli* antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet, **221**
Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis, **654**
Detection of cytokine producing cells in the synovial membrane of rheumatoid arthritis, **525** *abst*
Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis, **970**
Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis, **916**
Does rheumatoid arthritis improve after HIV-1 infection? A case report, **774** *abst*
Early rheumatoid arthritis: time to aim for remission?, **944**
Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis, **137**
Effect of long term intramuscular gold therapy on the seroprevalence of *Helicobacter pylori* in patients with early rheumatoid arthritis: *correspondence*, **437**
Endocrine disorders in rheumatoid arthritis, **772** *abst*
Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis, **256**
Expression of CD68 synovial fibroblasts in rheumatoid arthritis, **525** *abst*
Gene therapy for arthritis, **769** *abst*
High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis, **308**
Hip involvement in early rheumatoid arthritis, **45**
Human chimaeric antibody response in rheumatoid arthritis patients after treatment with a chimaeric anti-CD4 monoclonal antibody CM-T412, **771** *abst*
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis, **345**
Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis, **25**
Increased C reactive protein is a good predictor of functional outcome in early rheumatoid arthritis, **776** *abst*
Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis, **713**
Interleukin-1 expression by neutrophils in rheumatoid arthritis, **930**
Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis, **318**
Is rheumatoid arthritis a failure of B cell death in synovium? *hypothesis*, **696**
Isolated nail fold vasculitis in rheumatoid arthritis, **927**
Lack of influence of non-inherited maternal HLA-DR alleles on susceptibility to rheumatoid arthritis, **311**
Long term follow up of patients with active rheumatoid arthritis injected with murine idiotypic class II monoclonal antibodies, **771** *abst*
Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines, **382**
Microalbuminuria in patients with rheumatoid arthritis, **189**
Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies, **355**
Pathogenesis of rheumatoid arthritis: an overview, **759** *abst*
Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association, **775** *abst*
Pharmacokinetic profile of a new formulation of cyclosporin in patients with rheumatoid arthritis after conversion from the standard formulation, **774** *abst*
Phase II clinical trials with leflunomide in rheumatoid arthritis, **764** *abst*
Predominance of HLA-DRB1*0405 in Korean patients with rheumatoid arthritis, **988**
Prognosis features and outcome of early rheumatoid arthritis, **770** *abst*
Prostanoid modulation of synovial CD4 T cell cytotoxic function in rheumatoid arthritis, **775** *abst*
*Proteus*—is it a likely aetiological factor in chronic polyarthritis? *leader*, **157**
Radiographic assessment of damage in rheumatoid arthritis: a contribution to a standardised approach in multicentre studies, **772** *abst*
Radiological progression in rheumatoid arthritis relates to macrophage population in the synovium, **526** *abst*
Recombinant human soluble interleukin-1 receptor as potential treatment for rheumatoid arthritis, **769** *abst*
Regulation of cellular adhesion in rheumatoid arthritis by corticosteroids, **765** *abst*
Regulation of rheumatoid factors in physiological responses and in rheumatoid arthritis, **760** *abst*
Rheumatoid arthritis, corticosteroid therapy and hip fracture, **49**
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis, **801**
Secondary acute myeloid leukaemia with 7q– complicating azathioprine treatment for rheumatoid arthritis: *correspondence*, **155**
Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate: *matters arising*, **155**
Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and *Proteus mirabilis* in rheumatoid arthritis, **216**
Similar anti-*Proteus mirabilis* titres in $P_1$ positive and $P_1$ negative individuals with rheumatoid arthritis: *matters arising*, **607**
Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis?, **948**
Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients, **881**
Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients, **708**
Synovial hyaluronate in rheumatoid arthritis binds Clq and is covalently bound to antibodies: a model for chronicity, **408**
Thalidomide and pentoxifylline in rheumatoid arthritis: preliminary results of an open study, **773** *abst*
The semeiology of arthritis: discriminating between patients on the basis of their symptoms, **924**
Treatment of rheumatoid arthritis with engineered human antibody to tumour necrosis factor α: CDP571, **767** *abst*
Treatment of rheumatoid arthritis with recombinant soluble tumour necrosis factor receptor p80 fusion protein, **767** *abst*
Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis, **144**
Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone, **820**
Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis, **815**
Why the gender difference in susceptibility to rheumatoid arthritis? *leader*, **694**
Work disability in early rheumatoid arthritis, **455**

**Rheumatoid arthritis/polymyositis overlap syndrome,** Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome: *correspondence*, **780**

**Rheumatoid factor**
Clinical implications of IgA rheumatoid factor subclasses, **578**
Regulation of rheumatoid factors in physiological responses and in rheumatoid arthritis, **760** *abst*
Rheumatoid factor, chronic arthritis and mortality, **811**

**Rheumatoid joint,** CD4 T cells in the rheumatoid joint are oligoclonally activated and change during the course of disease, **314**

**Rheumatoid joint destruction,** Cellular basis of rheumatoid joint destruction: expression of oncogenes, adhesion molecules and cartilage degrading enzymes, **524** *abst*

**Rheumatoid lesion**
Mast cells and matrix degradation at the rheumatoid lesion, **525** *abst*
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies, **896**

**Rheumatoid synovitis,** Radiolabelled lymphocyte migration in rheumatoid synovitis, **39**

**Rheumatology**
Economic evaluation in rheumatology: a necessity for clinical studies: *leader*, **863**
Rheumatology education and management skills in general practice: a national study of trainees, **735**

**Rheumatology outpatients,** Comparison of clinical and self reported diagnosis for rheumatology outpatients, **850**

**Ribozymes,** Ribozymes: possible use in rheumatic disorders, **768** *abst*

**Rotterdam Study,** Association of locomotor complaints and disability in the Rotterdam study, **721**

**Salivary glands,** Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis, **209**

**Sciatica,** Sciatica in degenerative spondylolisthesis of the lumbar spine, **539**

**Scintigraphy,** Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis, **856**

**Scleroderma**
Expression of ectopeptidases in scleroderma, **111**
HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), **983**
Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies, **69**
Small bowel telangiectasia in scleroderma: *correspondence*, **78**
**Sclerotic vertebral lesions,** Paraplegia with sclerotic vertebral lesions: *lesson of the month*, **20**
**Self protein,** Induction of autoantibodies against a self protein, **773** *abst*
**Self reported diagnosis,** Comparison of clinical and self reported diagnosis for rheumatology outpatients, **850**
**Semeiology,** The semeiology of arthritis: discriminating between patients on the basis of their symptoms, **924**
**Seronegative arthropathies,** Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies: *leader*, **329**
**Serum,** Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis, **886**
**Sex hormones,** Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses: *review*, **6**
**Shoulder disorders**
Community survey of shoulder disorders in the elderly to assess the natural history and effects of treatment, **152**
Progressive shoulder arthropathy, **168**
Shoulder disorders in general practice: incidence, patient characteristics, and management, **959**
**Shoulder tendon biopsy,** Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases, **571**
**Sialoadenitis,** Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis, **209**
**Sickle cell disease,** Rheumatological manifestations of haematological diseases: review, **787**
**Sideroblastic anaemia,** Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis: *correspondence*, **529**
**Silent myocardial infarction,** Silent myocardial infarction in Wegener's granulomatosis: *correspondence*, **233**
**Sjögren's syndrome**
Bronchial hyperreactivity in systemic sclerosis patients: influence of associated Sjögren's syndrome, **636**
Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis, **209**
Defective repair of $O^6$-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma, **229**
Primary Sjögren's syndrome in men, **748**
Transforming growth factor β2 in labial salivary glands in Sjögren's syndrome, **744**
**Sjögren's syndrome associated arthritis,** Successful application of high dose intravenous immunoglobulins in Sjögren's syndrome associated arthritis: *correspondence*, **936**
**Skeletal evidence,** Skeletal evidence of osteoarthritis: a palaeopathological perspective, **443**
**Skeletal tuberculosis,** Beware the steroid responsive nature of a pyrexial illness: *lesson of the month*, **451**
**Small bowel,** Small bowel telangiectasia in scleroderma: *correspondence*, **78**
**Spain,** Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients, **881**
**Spinal diseases,** Commented glossary for rheumatic spinal diseases, based on pathology, **615**
**Spinal epidural abscess,** Paraplegia with sclerotic vertebral lesions: *lesson of the month*, **20**
**Spinal osteoarthrosis,** Bone mineral density and bone turnover in spinal osteoarthrosis, **867**
**Splenic cells,** Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus, **471**
**Spondyloarthropathy**
Autosomal dominant undifferentiated spondyloarthropathy not related to the HLA system: *matters arising*, **686**
Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7, **125**
**Spondylolisthesis,** Sciatica in degenerative spondylolisthesis of the lumbar spine, **539**
**Staphylococcal enterotoxin B**
Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis, **713**
Staphylococcal enterotoxin B increases the severity of type II collagen induced arthritis in mice, **298**
***Staphylococcus aureus,*** *Staphylococcus aureus* triggered reactive arthritis, **131**
**Steroids**
Beware the steroid responsive nature of a pyrexial illness: *lesson of the month*, **451**
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis, **801**
Steroid induced osteoporosis: an opportunity for prevention?, **66**
**Stiff collar,** A stiff collar can restrict atlantoaxial instability in rheumatoid cervical spine in selected cases, **305**
**Still's disease**
Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France, **567**
Increased serum IgE level and interleukin-4 release from cultured lymphocytes from a patient with adult onset Still's disease, **752**
**Stress,** Cardiovascular functional disorder and stress among patients having neck-shoulder symptoms, **494**
**Sulphasalazine,** Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis, **256**
**Superantigens,** Reactivation of bacterial cell wall induced arthritis and alteration of T cells by native and mutant superantigens, **524** *abst*
**Sweet's syndrome,** Sweet's syndrome associated with undifferentiated connective tissue syndrome: *correspondence*, **937**
**Swollen joints,** Imaging the swollen joint in the young patient, **333**
**Symptoms,** The semeiology of arthritis: discriminating between patients on the basis of their symptoms, **924**
**Synovial cells,** Interleukin-1 receptor antagonist production in cultured synovial cells from patients with rheumatoid arthritis and osteoarthritis, **318**
**Synovial effusions,** Physicochemical properties of human synovial effusions in osteoarthritis patients discontinued from anti-inflammatory medication, **527** *abst*
**Synovial fibroblast cultures,** Influence of endogenous cyclooxygenase product(s) on synovial fibroblast cultures, **528** *abst*
**Synovial fibroblasts**
Activation of synovial fibroblasts in rheumatoid arthritis, **501**
Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts, **560**
Expression of CD68 synovial fibroblasts in rheumatoid arthritis, **525** *abst*
**Synovial flow,** Intravenous Gd-DTPA enhancement of joint fluid on magnetic resonance imaging: a measurement of transsynovial flow?, **435** *abst*
**Synovial fluid**
Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis, **886**
Effect of synovial fluid hyaluronan on the clearance of albumin from the canine knee, **433**
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis, **345**
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid, **33**
Knee joint synovial fluid content of aggrecan predicts knee/hip joint destruction in rheumatoid arthritis, **528** *abst*
Persistence of parvovirus B19 in synovial fluid and bone marrow, **597**
Synovial perfusion and synovial fluid solutes, **424**
**Synovial fluid lymphocytes,** Expression of CD44 on rheumatoid synovial fluid lymphocytes, **566**
**Synovial fluid macromolecules,** Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules, **417**
**Synovial fluid neutrophils**
Expression of Fcγ receptors on synovial fluid neutrophils and activation by soluble immune complexes, **778** *abst*
Human blood and synovial fluid neutrophils cultured in vitro undergo programmed cell death which is promoted by the addition of synovial fluid, **910**
**Synovial fluid pressure**
Feeling the pressure: *leader*, **611**
Intra-articular pressure changes in rheumatoid and normal peripheral joints, **670**
**Synovial hyaluronate,** Synovial hyaluronate in rheumatoid arthritis binds Clq and is covalently bound to antibodies: a model for chronicity, **408**
**Synovial intimal cell layer,** Extracellular matrix of the synovial intimal cell layer, **404**
**Synovial intimal fibroblasts,** Synovial intimal fibroblasts, **395**
**Synovial irritants,** Synovial irritants: crystals, microbes and others —their implications for diagnosis, pathogenesis and therapy, **516**

**Synovial joints,** Synovial joints are immune to metastasis, **436** *abst*
**Synovial like peri-implant tissues,** UDPGD activity and VCAM-1 in synovial like peri-implant tissues, **525** *abst*
**Synovial lymphocytes,** Antibody expression by synovial lymphocytes in rheumatolid arthritis is suggestive of local clonal proliferation, **527** *abst*
**Synovial macrophages,** Synovial macrophages, **392**
**Synovial mast cells,** Nimesulide, a sulphonanilide non-steroidal anti-inflammatory drug, inhibits mediator release from human synovial mast cells, **775** *abst*
**Synovial membrane**
Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis, **654**
Detection of cytokine producing cells in the synovial membrane of rheumatoid arthritis, **525** *abst*
Effect of gold treatment on cytokine expression in synovium: *matters arising*, **779**
Immunohistological analysis of synovial membrane in ankylosing spondylitis: implications for immunotherapy, **772** *abst*
Synovial membrane cellularity and vascularity, **511**
**Synovial perfusion,** Synovial perfusion and synovial fluid solutes, **424**
**Synovial tissue,** Electron spin resonance spectroscopic demonstration of the generation of reactive oxygen species by diseased human synovial tissue following ex vivo hypoxia-reoxygenation, **94**
**Synovial volume,** Measurement of synovial volume and rates of synovial enhancement with Gd-DTPA enhanced magnetic resonance imaging, **435** *abst*
**Synoviocytes,** Interaction between synoviocytes and extracellular matrix in vitro, **413**
**Synovitis**
Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac and hyaluronan induced targeting technology, **766** *abst*
Imaging the swollen joint in the young patient, **333**
Matrix metalloproteinases and cartilage degradation, **765** *abst*
Mesenchymal reaction, **764** *abst*
Metalloproteinases, cytokines and angiogenesis, **765** *abst*
Multinucleate cells in pigmented villonodular synovitis express osteoclast markers, **436** *abst*
Prospective sonographic and arthroscopic evaluation of proliferative knee joint synovitis, **771** *abst*
Regulation of cellular adhesion in rheumatoid arthritis by corticosteroids, **765** *abst*
Regulation of gene transcription by glucocorticoids, **766** *abst*
Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome?, **681**
**Synovium**
Differential distribution of annexins-I, -II, -IV, and -VI in synovium, **841**
Fluid movement across synovium in healthy joints: role of synovial fluid macromolecules, **417**
Glycosaminoglycan concentration in rabbit synovium and its relation to pressure induced increased permeability, **435** *abst*
Innervation of the synovium, **398**
Is rheumatoid arthritis a failure of B cell death in synovium? *hypothesis*, **696**
Radiological progression in rheumatoid arthritis relates to macrophage population in the synovium, **526** *abst*
Second International Meeting on Synovium, Canterbury, September 1994, consensus statement, **389** abstracts, **435**, **524**
**Systemic lupus erythematosus**
Brown's syndrome: an important cause of diplopia in systemic lupus erythematosus: *correspondence*, **934**
Clinical and histological aspects of intravenous immunoblobulin treatment of systemic lupus erythematosus, **770** *abst*
Controversies in lupus: nervous system involvement: *review*, **159**
Distribution of cases of systemic lupus erythematosus at time of first symptom in an urban area, **891**
Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus, **361**
HLA associations of systemic lupus erythematosus in Chinese from Singapore: *correspondence*, **687**
HLA class II antigens associated with systemic lupus erythematosus in black South Africans, **678**
Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus, **117**
Loss of bone mineral density in premenopausal women with systemic lupus erythematosus, **274**
Phospholipid binding specificities and idiotype expression of hybridoma derived monoclonal autoantibodies from splenic cells of patients with systemic lupus erythematosus, **471**
Prevalence of $\beta_2$-glycoprotein I antibody in systemic lupus erythematosus patients with $\beta_2$-glycoprotein I dependent antiphospholipid antibodies, **73**
**Systemic sclerosis**
Bronchial hyperreactivity in systemic sclerosis patients: influence of associated Sjögren's syndrome, **636**
Exposure to chemicals and systemic sclerosis: *matters arising*, **529**
HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), **983**
Increased prevalence of symptomatic macrovascular disease in systemic sclerosis, **853**
Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis, **856**
Pericardial tamponade preceding cutaneous involvement in systemic sclerosis: *correspondence*, **687**
Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension, **730**

**T cell reactivity,** T cell reactivity to human type II collagen, **773** *abst*
**T cell receptor δ/CD3-4,** Signalling by TCRδ/CD3, CD28 and CTLA-4, **763** *abst*
**T cell receptor peptides**
Mechanism of action of T cell receptor antagonist peptides, **761** *abst*
T cell receptor peptide vaccination, **762** *abst*
**T cell receptor usage,** Immune mediated diseases are characterised by limited T cell receptor usage: disease expression may be regulated by naturally occurring T lymphocytes that recognise T cell receptor sequences, **760** *abst*
**T cell recognition,** T cell recognition of mouse type II collagen in mice, **770** *abst*
**T cells**
Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies, **69**
Reactivation of bacterial cell wall induced arthritis and alteration of T cells by native and mutant superantigens, **524** *abst*
**T helper-1 activation,** Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4, **836**
**Tamponade,** Pericardial tamponade preceding cutaneous involvement in systemic sclerosis: *correspondence*, **687**
**TAP polymorphism,** TAP polymorphism in patients with Behçet's disease, **386**
**99mTc-HMPAO,** Radiolabelled lymphocyte migration in rheumatoid synovitis, **39**
**Teaching,** Ulnar drift: or what not to teach students: *leader*, **235**
**Teenager,** Teenager with an irritable hip, anaemia and malaise: *masterclass*, **701**
**Telangiectasia,** Small bowel telangiectasia in scleroderma: *correspondence*, **78**
**Tenidap,** Immunomodulatory properties of tenidap, **768** *abst*
**Th1 and Th2 cytokines,** Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts, **560**
**Thalassaemia,** Rheumatological manifestations of haematological diseases: *review*, **787**
**Thalidomide,** Thalidomide and pentoxifylline in rheumatoid arthritis: preliminary results of an open study, **773** *abst*
**Therapeutic benefit,** Clinical and radiological outcome measures, **769** *abst*
**Thrombogenic events,** Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease, **726**
**TIMP-1 and TIMP-2,** Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis, **25**
**Tissue inhibitor of metalloproteinases,** Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases, **571**
**Tolerance**
Nasal tolerance, **761** *abst*
Oral tolerance in autoimmune diseases, **761** *abst*
Results of a German study of oral tolerance, **761** *abst*
**Total hip arthroplasty,** Extreme variations in racial rates of total hip arthroplasty for primary coxarthrosis: a population-based study in San Francisco, **107**
**Transforming growth factor β2,** Transforming growth factor β2 in labial salivary glands in Sjögren's syndrome, **744**
**Transforming growth factors,** Ankylosing spondylitis, IgA, and transforming growth factors: *hypothesis*, **544**
**Transgenic analyses,** Transgenic analyses of the role of tumour necrosis factor and interleukin-1 in arthritis, **767** *abst*

**Triamcinolone hexacetonide,** Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response, **379**
**Triglyceride levels,** Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients: *correspondence*, **609**
**Tryptase/chymase phenotype,** Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion, **549**
**Tuberculosis**
Antibody to *Mycobacterium tuberculosis* 65 kDa heat shock protein in patients with rheumatoid arthritis, **225**
Beware the steroid responsive nature of a pyrexial illness: *lesson of the month*, **451**
Don't forget tuberculosis: *lesson of the month*, **174**
Progressive shoulder arthropathy, **168**
**Tumour necrosis factor**
Anti-tumour necrosis factor treatment in arthritis in mice and in humans, **767** *abst*
Transgenic analyses of the role of tumour necrosis factor and interleukin-1 in arthritis, **767** *abst*
**Tumour necrosis factor α**
A tumour necrosis factor α polymorphism is not associated with rheumatoid arthritis, **601**
Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNFα, **904**
Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies, **366**
Treatment of rheumatoid arthritis with engineered human antibody to tumour necrosis factor α: CDP571, **767** *abst*
**Tumour necrosis factor receptor,** Treatment of rheumatoid arthritis with recombinant soluble tumour necrosis factor receptor p80 fusion protein, **767** *abst*

**UDPGD activity,** UDPGD activity and VCAM-1 in synovial like peri-implant tissues, **525** *abst*
**Ulnar drift,** Ulnar drift: or what not to teach students: *leader*, **235**
**Ultrasound,** Prospective sonographic and arthroscopic evaluation of proliferative knee joint synovitis, **771** *abst*
**Undifferentiated connective tissue syndrome,** Sweet's syndrome associated with undifferentiated connective tissue syndrome: *correspondence*, **937**
**Undifferentiated spondyloarthropathy,** Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7, **125**
**Uric acid,** Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients: *correspondence*, **609**

**Vaccination,** T cell receptor peptide vaccination, **762** *abst*
**Vasculitis**
Asymmetric rheumatoid vasculitis in a hemiplegic patient: *correspondence*, **532**
Isolated nail fold vasculitis in rheumatoid arthritis, **927**
**Vegetarian diet,** Decrease in anti-*Proteus mirabilis* but not anti-*Escherichia coli* antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet, **221**
**Vertebral fracture**
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis, **801**
Vertebral fracture induced by chronic contained rupture of aortic aneurysm: *correspondence*, **437**
**Vertebral hyperostosis,** Vertebral hyperostosis and diabetes mellitus, **375**

**Wegener's granulomatosis**
Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis, **991**
Silent myocardial infarction in Wegener's granulomatosis: *correspondence*, **233**
Subcutaneous nodules in a patient with polyarthritis: *lesson of the month*, **796**
Wegener's granulomatosis of the elderly: a case report of uncommon severe gangrene of the feet: *correspondence*, **328**
**Work disability,** Work disability in early rheumatoid arthritis, **455**

**Yersinia triggered reactive arthritis,** Biologically relevant and evolutionarily conserved proteins are major target antigens for the cellular immune system in yersinia triggered reactive arthritis, **774** *abst*

**Zygapophysial joint pain,** Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain, **100**
**Zymosan arthritis,** Zymosan arthritis: a model of inflammatory erosive joint disease, **527** *abst*